Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Previous issues

Page Path
HOME > BROWSE ARTICLES > Previous issues
14 Previous issues
Filter
Filter
Article type
Keywords
Authors
Volume 34(3); September 2019
Prev issue Next issue
Review Articles
Thyroid
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
Jierui Liu, Yanqing Liu, Yansong Lin, Jun Liang
Endocrinol Metab. 2019;34(3):215-225.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.215
  • 11,642 View
  • 346 Download
  • 70 Web of Science
  • 65 Crossref
AbstractAbstract PDFPubReader   ePub   

The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine (RAI) therapy, which is an effective treatment for reducing the risk of recurrence, and even the mortality, of DTC. Whereas, the dedifferentiation of DTC could influence the expression of functional NIS, thereby reducing the efficacy of RAI therapy in advanced DTC. Genetic alternations (such as BRAF and the rearranged during transfection [RET]/papillary thyroid cancer [PTC] rearrangement) have been widely reported to be prominently responsible for the onset, progression, and dedifferentiation of PTC, mainly through activating the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling cascades. These genetic alternations have been suggested to associate with the reduced expression of iodide-handling genes in thyroid cancer, especially the NIS gene, disabling iodine uptake and causing resistance to RAI therapy. Recently, novel and promising approaches aiming at various targets have been attempted to restore the expression of these iodine-metabolizing genes and enhance iodine uptake through in vitro studies and studies of RAI-refractory (RAIR)-DTC patients. In this review, we discuss the regulation of NIS, known mechanisms of dedifferentiation including the MAPK and PI3K pathways, and the current status of redifferentiation therapy for RAIR-DTC patients.

Citations

Citations to this article as recorded by  
  • Long-term impact of prophylactic central neck dissection in non-invasive classic papillary thyroid carcinoma
    Zehang Xu, Zhuochao Mao, Shitu Chen, Zhe Mo, Jie Zhou, Zhendong Chen, Rasa Zarnegar, Thomas J. Fahey III, Weibin Wang, Lisong Teng
    European Journal of Surgical Oncology.2024; 50(1): 107305.     CrossRef
  • Canine follicular cell and medullary thyroid carcinomas: Immunohistochemical characterization
    Jana Jankovic, Eve Tièche, Martina Dettwiler, Kerstin Hahn, Stephanie Scheemaeker, Martin Kessler, Sylvie Daminet, Sven Rottenberg, Miguel Campos
    Veterinary Pathology.2024; 61(4): 524.     CrossRef
  • The role of MAPK, notch and Wnt signaling pathways in papillary thyroid cancer: Evidence from a systematic review and meta-analyzing microarray datasets employing bioinformatics knowledge and literature
    Elham Amjad, Solmaz Asnaashari, Ali Jahanban-Esfahlan, Babak Sokouti
    Biochemistry and Biophysics Reports.2024; 37: 101606.     CrossRef
  • Diagnostic Performance of [18F]TFB PET/CT Compared with Therapeutic Activity [131I]Iodine SPECT/CT and [18F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma
    David Ventura, Matthias Dittmann, Florian Büther, Michael Schäfers, Kambiz Rahbar, Daniel Hescheler, Michael Claesener, Philipp Schindler, Burkhard Riemann, Robert Seifert, Wolfgang Roll
    Journal of Nuclear Medicine.2024; 65(2): 192.     CrossRef
  • Dihydrotanshinone I exhibits antitumor effects via β-catenin downregulation in papillary thyroid cancer cell lines
    Elisabetta Molteni, Federica Baldan, Giuseppe Damante, Lorenzo Allegri
    Scientific Reports.2024;[Epub]     CrossRef
  • Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib
    Pu Chen, Jianling Wang, Yao Yao, Yiping Qu, Meiju Ji, Peng Hou
    Endocrine.2024;[Epub]     CrossRef
  • Metabolomic screening of radioiodine refractory thyroid cancer patients and the underlying chemical mechanism of iodine resistance
    Weihui Zheng, Xi Tang, Jinyun Dong, Jianguo Feng, Min Chen, Xin Zhu
    Scientific Reports.2024;[Epub]     CrossRef
  • Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
    Fang Sui, Guanjie Wang, Juan Liu, Mengmeng Yuan, Pu Chen, Yao Yao, Shaoqiang Zhang, Meiju Ji, Peng Hou
    Cellular and Molecular Life Sciences.2024;[Epub]     CrossRef
  • Targeting miR‐31 represses tumourigenesis and dedifferentiation of BRAFV600E‐associated thyroid carcinoma
    Peitao Zhang, Lizhao Guan, Wei Sun, Yu Zhang, Yaying Du, Shukai Yuan, Xiaolong Cao, Zhengquan Yu, Qiang Jia, Xiangqian Zheng, Zhaowei Meng, Xingrui Li, Li Zhao
    Clinical and Translational Medicine.2024;[Epub]     CrossRef
  • Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma
    Majdouline Bel Lakhdar, Ayat Mouaden, Mourad Zekri, Dounia Alami, Hamza Zarouf, Imad Ghfir, Hasnae Guerrouj
    World Journal of Nuclear Medicine.2024;[Epub]     CrossRef
  • The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review
    Odysseas Violetis, Panagiota Konstantakou, Ariadni Spyroglou, Antonios Xydakis, Panagiotis B. Kekis, Sofia Tseleni, Denise Kolomodi, Manousos Konstadoulakis, George Mastorakos, Maria Theochari, Javier Aller, Krystallenia I. Alexandraki
    Journal of Personalized Medicine.2024; 14(6): 654.     CrossRef
  • Ubiquitin-modifying enzymes in thyroid cancer:Mechanisms and functions
    Xingmin Xiong, BenBen Huang, Zhe Gan, Weixiang Liu, Yang Xie, Jianing Zhong, Xiangtai Zeng
    Heliyon.2024; 10(13): e34032.     CrossRef
  • Molecular Perspectives in Radioactive Iodine Theranostics: Current Redifferentiation Protocols for Mis-Differentiated Thyroid Cancer
    Seza A. Gulec, Cristina Benites, Maria E. Cabanillas
    Journal of Clinical Medicine.2024; 13(13): 3645.     CrossRef
  • Lipid‐Peptide‐mRNA Nanoparticles Augment Radioiodine Uptake in Anaplastic Thyroid Cancer
    Qinglin Li, Lizhuo Zhang, Jiayan Lang, Zhuo Tan, Qingqing Feng, Fei Zhu, Guangna Liu, Zhangguo Ying, Xuefei Yu, He Feng, Heqing Yi, Qingliang Wen, Tiefeng Jin, Keman Cheng, Xiao Zhao, Minghua Ge
    Advanced Science.2023;[Epub]     CrossRef
  • Case Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re-differentiation strategy?
    Bentolhoda Hadad, Emran Askari, Seyed Rasoul Zakavi, Kamran Aryana, Soheila Erfani, Pegah Sahafi, Nima Nabavi, Atena Aghaee
    Frontiers in Nuclear Medicine.2023;[Epub]     CrossRef
  • Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy
    Yujia Liu, Jiafeng Wang, Xiaoping Hu, Zongfu Pan, Tong Xu, Jiajie Xu, Liehao Jiang, Ping Huang, Yiwen Zhang, Minghua Ge
    Drug Resistance Updates.2023; 68: 100939.     CrossRef
  • The role of miR-139-5p in radioiodine-resistant thyroid cancer
    V. Pecce, M. Sponziello, A. Verrienti, G. Grani, L. Abballe, S. Bini, S. Annunziata, G. Perotti, M. Salvatori, L. Zagaria, V. Maggisano, D. Russo, S. Filetti, C. Durante
    Journal of Endocrinological Investigation.2023; 46(10): 2079.     CrossRef
  • Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma
    Hang-Seok Chang, Yonjung Kim, So Young Lee, Hyeok Jun Yun, Ho-Jin Chang, Ki Cheong Park
    International Journal of Molecular Sciences.2023; 24(8): 7069.     CrossRef
  • Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer
    Diego Claro de Mello, Kelly Cristina Saito, Marcella Maringolo Cristovão, Edna Teruko Kimura, Cesar Seigi Fuziwara
    International Journal of Molecular Sciences.2023; 24(9): 7872.     CrossRef
  • Effects of apitherapy against salivary gland disorder after radioactive iodine therapy for differentiated thyroid cancer
    Kenta Nomura, Michihiro Nakayama, Atsutaka Okizaki
    Annals of Nuclear Medicine.2023; 37(8): 462.     CrossRef
  • Could Oxidative Stress Play a Role in the Development and Clinical Management of Differentiated Thyroid Cancer?
    Maria Kościuszko, Angelika Buczyńska, Adam Jacek Krętowski, Anna Popławska-Kita
    Cancers.2023; 15(12): 3182.     CrossRef
  • The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib
    Yuanna Ling, Xiaoli Xiong, Jiaxin Luo, Quanliang Zou, Pan Chen, Liqin Pan, Man Long, Huijuan Feng, Wei Ouyang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer
    Lu Zhang, Zhi Li, Meng Zhang, Huangren Zou, Yuke Bai, Yanlin Liu, Juan Lv, Ling Lv, Pengjie Liu, Zhiyong Deng, Chao Liu
    Medical Oncology.2023;[Epub]     CrossRef
  • Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
    Yansong Lin, Shukui Qin, Hui Yang, Feng Shi, Aimin Yang, Xingmin Han, Bin Liu, Zhiyong Li, Qinghai Ji, Lijun Tang, Zhiyong Deng, Yong Ding, Wei Fu, Xianhe Xie, Linfa Li, Xiaohui He, Zhongwei Lv, Qingjie Ma, Zan Shen, Zhuming Guo, Zhendong Chen, Yali Cui,
    Clinical Cancer Research.2023; 29(15): 2791.     CrossRef
  • A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies
    Riya Thapa, Gaurav Gupta, Asif Ahmad Bhat, Waleed Hassan Almalki, Sami I. Alzarea, Imran Kazmi, Shakir Saleem, Ruqaiyah Khan, Najla Altwaijry, Harish Dureja, Sachin Kumar Singh, Kamal Dua
    International Journal of Biological Macromolecules.2023; 253: 127375.     CrossRef
  • Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer
    Yuna Kim, Hyeok Jun Yun, Kyung Hwa Choi, Chan Wung Kim, Jae Ha Lee, Raymond Weicker, Seok-Mo Kim, Ki Cheong Park
    International Journal of Molecular Sciences.2023; 24(22): 16413.     CrossRef
  • Utilizing CD44v6 and V600EBRAF-mutation for in vitro targeted combination therapy of thyroid carcinomas
    A.C.L. Mortensen, J. Imgenberg-Kreuz, D. Spiegelberg, J. Botling, M. Nestor
    Heliyon.2023; 9(12): e22594.     CrossRef
  • Advancements in theranostic applications: exploring the role of fibroblast activation protein inhibition tracers in enhancing thyroid health assessment
    Yuhua Wang, Ye Liu, Huixia Geng, Wanchun Zhang
    EJNMMI Research.2023;[Epub]     CrossRef
  • Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer
    Christos Cortas, Haris Charalambous
    Life.2023; 14(1): 22.     CrossRef
  • microRNA-181a promotes the oncogene S100A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C
    Y. Wang, H. Ye, Y. Yang, J. Li, A. Cen, L. Zhao
    Journal of Endocrinological Investigation.2022; 45(1): 17.     CrossRef
  • Systemic Therapy in Thyroid Cancer
    Amit Kumar Agrawal, Vanita Noronha, Vijay Patil, Nandini Menon, Akhil Kapoor, Anuradha Chougule, Pratik Chandrani, Kumar Prabhash
    Indian Journal of Surgical Oncology.2022; 13(1): 68.     CrossRef
  • Small activating RNA-activated NIS gene promotes 131I uptake and inhibits thyroid cancer via AMPK/mTOR pathway
    Li Jia, Yan Chen, Fukun Chen, Juan Lv, Yanling Li, Fei Hou, Zhixian Yang, Zhiyong Deng
    Pathology - Research and Practice.2022; 229: 153735.     CrossRef
  • Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer
    Hyeok Jun Yun, Minki Kim, Sang Yong Kim, Sungsoon Fang, Yonjung Kim, Hang-Seok Chang, Ho-Jin Chang, Ki Cheong Park
    International Journal of Molecular Sciences.2022; 23(2): 699.     CrossRef
  • Comprehensive Analysis of the Prognosis and Drug Sensitivity of Differentiation-Related lncRNAs in Papillary Thyroid Cancer
    Wenlong Wang, Ning Bai, Xinying Li
    Cancers.2022; 14(5): 1353.     CrossRef
  • American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment
    David C. Shonka, Alan Ho, Ashish V. Chintakuntlawar, Jessica L. Geiger, Jong C. Park, Nagashree Seetharamu, Sina Jasim, Amr H. Abdelhamid Ahmed, Keith C. Bible, Marcia S. Brose, Maria E. Cabanillas, Kirsten Dabekaussen, Louise Davies, Dora Dias‐Santagata,
    Head & Neck.2022; 44(6): 1277.     CrossRef
  • State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer
    Horatiu Silaghi, Vera Lozovanu, Carmen Emanuela Georgescu, Cristina Pop, Bogdana Adriana Nasui, Adriana Florinela Cătoi, Cristina Alina Silaghi
    International Journal of Molecular Sciences.2022; 23(7): 3470.     CrossRef
  • Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers
    Ji Min Oh, Ramya Lakshmi Rajendran, Prakash Gangadaran, Chae Moon Hong, Ju Hye Jeong, Jaetae Lee, Byeong-Cheol Ahn
    Cancers.2022; 14(7): 1782.     CrossRef
  • The Role of the Kinase Inhibitors in Thyroid Cancers
    Francesca Cuomo, Claudio Giani, Gilda Cobellis
    Pharmaceutics.2022; 14(5): 1040.     CrossRef
  • In Silico Screening and Validation of PDGFRA Inhibitors Enhancing Radioiodine Sensitivity in Thyroid Cancer
    Xuefei Yu, Xuhang Zhu, Lizhuo Zhang, Jiang-Jiang Qin, Chunlai Feng, Qinglin Li
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Clinical and prognosis value of the number of metastatic lymph nodes in patients with papillary thyroid carcinoma
    Ling Zhan, Hong-fang Feng, Xi-zi Yu, Ling-rui Li, Jun-long Song, Yi Tu, Jing-ping Yuan, Chuang Chen, Sheng-rong Sun
    BMC Surgery.2022;[Epub]     CrossRef
  • Radionuclide 131I-labeled albumin-indocyanine green nanoparticles for synergistic combined radio-photothermal therapy of anaplastic thyroid cancer
    Xuemei Zhang, Ziyu Yan, Zhaowei Meng, Ning Li, Qiang Jia, Yiming Shen, Yanhui Ji
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Re-evaluation of the role of autophagy in thyroid cancer treatment
    Darya Kazakova, Mika Shimamura, Tomomi Kurashige, Koichiro Hamada, Yuji Nagayama
    Endocrine Journal.2022; 69(7): 847.     CrossRef
  • Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges
    Suliman Salih, Ajnas Alkatheeri, Wijdan Alomaim, Aisyah Elliyanti
    Molecules.2022; 27(16): 5231.     CrossRef
  • Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma
    Seok-Mo Kim, Keunwan Park, Jin Hong Lim, Hyeok Jun Yun, Sang Yong Kim, Kyung Hwa Choi, Chan Wung Kim, Jae Ha Lee, Raymond Weicker, Cheol-Ho Pan, Ki Cheong Park
    International Journal of Molecular Sciences.2022; 23(18): 10378.     CrossRef
  • Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma
    延泽 刘
    Advances in Clinical Medicine.2022; 12(09): 8499.     CrossRef
  • Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer
    Jing Zhang, Aomei Zhao, Xi Jia, Xinru Li, Yiqian Liang, Yan Liu, Xin Xie, Xijie Qu, Qi Wang, Yuemin Zhang, Rui Gao, Yan Yu, Aimin Yang
    International Journal of Molecular Sciences.2022; 23(18): 10709.     CrossRef
  • miR-451a suppresses papillary thyroid cancer cell proliferation and invasion and facilitates apoptosis through targeting DCBLD2 and AKT1
    Jiuting Tan, Chunpu Li, Lijue Ren, Xiaohui Zhu, Fei Hua, Yuming Fu
    Molecular and Cellular Probes.2022; 66: 101863.     CrossRef
  • Anxiety and depression status prior to radioactive iodine therapy among differentiated thyroid cancer patients during the COVID‑19 pandemic
    Tingting Qiao, Dingwei Gao, Junyu Tong, Yun Shen, Jiayue Ma, Zhongwei Lv, Dan Li
    Supportive Care in Cancer.2022; 30(12): 10169.     CrossRef
  • Different Expression of Thyroid-Specific Proteins in Thyroid Cancer Cells between 2-Dimensional (2D) and 3-Dimensional (3D) Culture Environment
    Ji Min Oh, Prakash Gangadaran, Ramya Lakshmi Rajendran, Chae Moon Hong, Jaetae Lee, Byeong-Cheol Ahn
    Cells.2022; 11(22): 3559.     CrossRef
  • Histone acetylation modifications: A potential targets for the diagnosis and treatment of papillary thyroid cancer
    Chongyang Chen, Jingfang Liu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter
    Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Tadashi Watabe, Kazuhiro Ooe, Takashi Yoshimura, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Koichi Fukase
    International Journal of Molecular Sciences.2022; 23(24): 15509.     CrossRef
  • Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
    Maaike Dotinga, Dennis Vriens, Floris H. P. van Velden, Mette K. Stam, Jan W. T. Heemskerk, Petra Dibbets-Schneider, Martin Pool, Daphne D. D. Rietbergen, Lioe-Fee de Geus-Oei, Ellen Kapiteijn
    Diagnostics.2022; 12(12): 3154.     CrossRef
  • Non-Apoptotic Programmed Cell Death in Thyroid Diseases
    Feihong Ji, Xinguang Qiu
    Pharmaceuticals.2022; 15(12): 1565.     CrossRef
  • Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial
    Yan-Song Lin, Hui Yang, Yong Ding, Yi-Zhuang Cheng, Feng Shi, Jian Tan, Zhi-Yong Deng, Zhen-Dong Chen, Rong-Fu Wang, Qing-Hai Ji, Rui Huang, Lin-Fa Li
    Thyroid.2021; 31(4): 607.     CrossRef
  • Radioactive iodine therapy may not improve disease‐specific survival in follicular variant papillary thyroid cancer without distant metastasis: A propensity score‐matched analysis
    Xiaofei Wang, Xun Zheng, Jingqiang Zhu, Zhihui Li, Tao Wei
    Head & Neck.2021; 43(6): 1730.     CrossRef
  • Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis
    Chaiho Jeong, Jeongmin Lee, Hyukjin Yoon, Jeonghoon Ha, Min-Hee Kim, Ja-Seong Bae, Chan-Kwon Jung, Jeong-Soo Kim, Moo-Il Kang, Dong-Jun Lim
    Cancers.2021; 13(4): 811.     CrossRef
  • Radio-Iodide Treatment: From Molecular Aspects to the Clinical View
    Antonio De la Vieja, Garcilaso Riesco-Eizaguirre
    Cancers.2021; 13(5): 995.     CrossRef
  • Advances of Nanomedicine in Radiotherapy
    Wei Liu, Bo Chen, Haocheng Zheng, Yun Xing, Guiyuan Chen, Peijie Zhou, Liting Qian, Yuanzeng Min
    Pharmaceutics.2021; 13(11): 1757.     CrossRef
  • Treatment Effect of Combining Lenvatinib and Vemurafenib for BRAF Mutated Anaplastic Thyroid Cancer
    Chae Moon Hong, Ji Min Oh, Prakash Gangadaran, Ramya Lakshmi Rajendran, Byeong-Cheol Ahn
    International Journal of Thyroidology.2021; 14(2): 127.     CrossRef
  • TNFα-mediated activation of NF-κB downregulates sodium-iodide symporter expression in thyroid cells
    Márcia Faria, Rita Domingues, Francisca Paixão, Maria João Bugalho, Paulo Matos, Ana Luísa Silva, Salvatore Papa
    PLOS ONE.2020; 15(2): e0228794.     CrossRef
  • Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
    Mohammad Al-Jundi, Shilpa Thakur, Sriram Gubbi, Joanna Klubo-Gwiezdzinska
    Cancers.2020; 12(8): 2104.     CrossRef
  • Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy
    Maaike Dotinga, Dennis Vriens, Floris van Velden, Linda Heijmen, James Nagarajah, Rodney Hicks, Ellen Kapiteijn, Lioe-Fee de Geus-Oei
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2020;[Epub]     CrossRef
  • Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radioiodine resistance
    Hongwei Gao, Peirong Bai, Lin Xiao, Mengjia Shen, Qiuxiao Yu, Yuanyuan Lei, Wenting Huang, Xiang Lin, Xinyi Zheng, Tao Wei, Yong Jiang, Feng Ye, Hong Bu
    Journal of Biological Chemistry.2020; 295(31): 10726.     CrossRef
  • Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer
    Dong Yun Lee, Yong-il Kim
    Clinical Nuclear Medicine.2020; 45(8): 604.     CrossRef
  • Combination of peroxisome proliferator–activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells
    Jui-Yu Chen, Jane-Jen Wang, Hsin-Chen Lee, Chin-Wen Chi, Chen-Hsen Lee, Yi-Chiung Hsu
    Journal of the Chinese Medical Association.2020; 83(10): 923.     CrossRef
Close layer
Obesity and Metabolism
Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
Eun-Jung Rhee
Endocrinol Metab. 2019;34(3):226-233.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.226
  • 11,381 View
  • 323 Download
  • 70 Web of Science
  • 74 Crossref
AbstractAbstract PDFPubReader   ePub   

Nonalcoholic fatty liver disease (NAFLD) is thought to stem from the body's inability to store excess energy in adipocytes; as such, it is commonly viewed as the hepatic manifestation of metabolic syndrome. The pathogenesis of NAFLD involves ectopic fat accumulation, which also takes place in the liver, muscle and visceral fat. NAFLD is rapidly becoming more widespread in Korea, with an estimated prevalence of 30% in adults. Type 2 diabetes mellitus (T2DM) and NAFLD share insulin resistance as a common pathophysiological mechanism, and each of these two diseases affects the development of the other. Recent studies have suggested that NAFLD is often present as a comorbidity in T2DM patients. The mutual interrelationship between these conditions is shown by findings suggesting that T2DM can exacerbate NAFLD by promoting progression to nonalcoholic hepatosteatosis or fibrosis, while NAFLD causes the natural course of diabetic complications to worsen in T2DM patients. It remains unknown whether one disease is the cause of the other or vice versa. In this review, I would like to discuss current epidemiological data on the associations between NAFLD and T2DM, and how each disease affects the course of the other.

Citations

Citations to this article as recorded by  
  • Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends
    Yujie Zhong, Tao Wang, Ruilin Luo, Jiayu Liu, Ruyi Jin, Xiaoli Peng
    Critical Reviews in Food Science and Nutrition.2024; 64(17): 5768.     CrossRef
  • Effect of exercise intervention on clinical parameters in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
    Yu Zeng, Xuemei Zhang, Wenling Luo, Yunjian Sheng
    European Journal of Gastroenterology & Hepatology.2024; 36(1): 1.     CrossRef
  • Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis
    Sven M. Francque, Alexander Hodge, Jerome Boursier, Ziad H. Younes, Gerardo Rodriguez-Araujo, Grace S. Park, Naim Alkhouri, Manal F. Abdelmalek
    Hepatology Communications.2024;[Epub]     CrossRef
  • Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
    Young-Hwan Park, Minji Sohn, So Yeon Lee, Soo Lim
    Diabetes & Metabolism Journal.2024; 48(2): 253.     CrossRef
  • Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
    强江 郭
    Advances in Clinical Medicine.2024; 14(03): 561.     CrossRef
  • Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe
    Maria Eleni Chondrogianni, Ioannis Kyrou, Theodoros Androutsakos, Christina-Maria Flessa, Evangelos Menenakos, Kamaljit Kaur Chatha, Yekaterina Aranan, Athanasios G. Papavassiliou, Eva Kassi, Harpal S. Randeva
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Obeticholic Acid and Insulin Sensitivity in Overweight Patients with Prediabetes
    H. Amer, M. Nesim, H. Mansour, E. Nasr, N. Ahmed
    Obesity and metabolism.2024;[Epub]     CrossRef
  • Multiple Definitions of Fatty Liver Disease: Which One Most Accurately Predicts Diabetes?
    Eun-Jung Rhee
    Endocrinology and Metabolism.2024; 39(2): 397.     CrossRef
  • The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
    Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii-Dizgah, Afsaneh Vosughi
    Annals of Military and Health Sciences Research.2024;[Epub]     CrossRef
  • Higher habitual intakes of flavonoids and flavonoid-rich foods are associated with a lower incidence of type 2 diabetes in the UK Biobank cohort
    Alysha S. Thompson, Amy Jennings, Nicola P. Bondonno, Anna Tresserra-Rimbau, Benjamin H. Parmenter, Claire Hill, Aurora Perez-Cornago, Tilman Kühn, Aedín Cassidy
    Nutrition & Diabetes.2024;[Epub]     CrossRef
  • Associations of sex-related and thyroid-related hormones with risk of metabolic dysfunction-associated fatty liver disease in T2DM patients
    Weihong Lu, Shangjian Li, Yuhua Li, Jingqi Zhou, Kai Wang, Ning Chen, Zhibin Li
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Diagnostic role of SPP1 and collagen IV in a rat model of type 2 diabetes mellitus with MASLD
    Shan Xiao, Xiao Bei Wang, Ye Yang, Qin Wang
    Scientific Reports.2024;[Epub]     CrossRef
  • Impact of dietary fiber intake on non-alcoholic fatty liver disease risk in Korean patients with obesity and type 2 diabetes mellitus
    Ji-Sook Park, Hina Akbar, Young-Seol Kim, Jung-Eun Yim
    Journal of Nutrition and Health.2024; 57(3): 282.     CrossRef
  • Utility of Indices Obtained during Medical Checkups for Predicting Fatty Liver Disease in Non-obese People
    Naoya Otsubo, Tatsuya Fukuda, Genhin Cho, Fumiaki Ishibashi, Tetsuya Yamada, Koshiro Monzen
    Internal Medicine.2023; 62(16): 2307.     CrossRef
  • Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs
    Yan Zhao, Wenli Zhao, Huaien Bu, Maeda Toshiyoshi, Ye Zhao
    Medicine.2023; 102(6): e32892.     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Metabolomics analysis reveals serum biomarkers in patients with diabetic sarcopenia
    Yuwei Tan, Xiaosong Liu, Yinping Yang, Baoying Li, Fei Yu, Wenqian Zhao, Chunli Fu, Xin Yu, Zhenxia Han, Mei Cheng
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition
    Shuangdi Duan, Nong Qin, Jiayi Pi, Pei Sun, Yating Gao, Lamei Liu, Zenghui Li, Ya Li, Liyang Shi, Qiang Gao, Ye Qiu, Songqing Tang, Chun-Hsiang Wang, Tzu-Ying Chen, Sin-Tian Wang, Kung-Chia Young, Hung-Yu Sun
    Hepatology.2023; 78(4): 1182.     CrossRef
  • The Influence of Metabolic Factors in Patients with Chronic Viral Hepatitis C Who Received Oral Antiviral Treatment
    Oana Irina Gavril, Radu Sebastian Gavril, Florin Mitu, Otilia Gavrilescu, Iolanda Valentina Popa, Diana Tatarciuc, Andrei Drugescu, Andrei Catalin Oprescu, Andreea Gherasim, Laura Mihalache, Irina Mihaela Esanu
    Metabolites.2023; 13(4): 571.     CrossRef
  • The bidirectional relationship between NAFLD and type 2 diabetes: A prospective population-based cohort study
    Minzhen Wang, Yanan Zhao, Yingqian He, Lulu Zhang, Jing Liu, Shan Zheng, Yana Bai
    Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(8): 1521.     CrossRef
  • Visceral fat: A key mediator of NAFLD development and progression
    Savita Bansal, Meenakshi Vachher, Taruna Arora, Bhupender Kumar, Archana Burman
    Human Nutrition & Metabolism.2023; 33: 200210.     CrossRef
  • Greater Severity of Steatosis Is Associated with a Higher Risk of Incident Diabetes: A Retrospective Longitudinal Study
    Ji Min Han, Jung Hwan Cho, Hye In Kim, Sunghwan Suh, Yu-Ji Lee, Jung Won Lee, Kwang Min Kim, Ji Cheol Bae
    Endocrinology and Metabolism.2023; 38(4): 418.     CrossRef
  • The role of TRIM family in metabolic associated fatty liver disease
    Jingyue Zhang, Yingming Zhang, Ze Ren, Dongmei Yan, Guiying Li
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Non-alcoholic fatty liver disease and diabetic retinopathy: Is there an association?
    Mathew Jacob, Mary Joseph, Jyothi Idiculla
    Journal of Family Medicine and Primary Care.2023; 12(9): 2028.     CrossRef
  • Camel whey protein improves diabetic liver injury by targeting ACMSD and promoting de novo NAD+ synthesis
    Zhihua Dou, Huaibin Yao, Yutong Xie, Ying Liu, Yang Gao, Jie Yang
    Journal of Functional Foods.2023; 110: 105835.     CrossRef
  • Gut microbiota and nonalcoholic fatty liver disease
    Boyeon Kim, Bukyung Kim
    Kosin Medical Journal.2023; 38(3): 169.     CrossRef
  • Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
    E.G. Mankieva, E.I. Kukhareva
    Dokazatel'naya gastroenterologiya.2023; 12(4): 103.     CrossRef
  • Body Fat Distribution, Glucose Metabolism, and Diabetes Status Among Older Adults: The Multiethnic Cohort Adiposity Phenotype Study
    Gertraud Maskarinec, Phyllis Raquinio, Bruce S. Kristal, Adrian A. Franke, Steven D. Buchthal, Thomas M. Ernst, Kristine R. Monroe, John A. Shepherd, Yurii B. Shvetsov, Loïc Le Marchand, Unhee Lim
    Journal of Epidemiology.2022; 32(7): 314.     CrossRef
  • Evaluation of the reciprocal interaction between hepatic steatosis and type 2 diabetes: a comparative analysis with respect to anti-diabetic treatment, glycemic control, renal and hepatic function
    Teslime Ayaz, Hatice Beyazal Polat, Bilgesah Kilictas
    International Journal of Diabetes in Developing Countries.2022; 42(3): 421.     CrossRef
  • Glycemic control, the unconsidered outcome in the treatment of nonalcoholic fatty liver disease
    Diego García-Compeán, Emanuela Orsi, Tsutomu Nishida, Ramesh Kumar
    Annals of Hepatology.2022; 27(1): 100648.     CrossRef
  • Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999–2016
    Pegah Golabi, James M. Paik, Michael Harring, Elena Younossi, Khaled Kabbara, Zobair M. Younossi
    Clinical Gastroenterology and Hepatology.2022; 20(12): 2838.     CrossRef
  • The Influence of Obesity and Metabolic Health on Vascular Health
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(1): 1.     CrossRef
  • Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials
    Xiaojuan Peng, Juan Li, Hailiang Zhao, Junlong Lai, Junqin Lin, Shaohui Tang
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
    Ji Cheol Bae, Lauren A. Beste, Kristina M. Utzschneider
    Endocrinology and Metabolism.2022; 37(3): 455.     CrossRef
  • Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(3): 415.     CrossRef
  • Structurally‐engineered fatty acid 1024 (SEFA‐1024) improves diet‐induced obesity, insulin resistance, and fatty liver disease
    Jordon D. Secor, Bennet S. Cho, Lumeng J. Yu, Amy Pan, Victoria H. Ko, Duy T. Dao, Michael Feigh, Lorenzo Anez‐Bustillos, Gillian L. Fell, David A. Fraser, Kathleen M. Gura, Mark Puder
    Lipids.2022; 57(4-5): 241.     CrossRef
  • Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study
    Ángel Arturo López-González, Bárbara Altisench Jané, Luis Masmiquel Comas, Sebastiana Arroyo Bote, Hilda María González San Miguel, José Ignacio Ramírez Manent
    Nutrients.2022; 14(14): 2795.     CrossRef
  • Captopril and Spironolactone can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting ABCA1 and microRNA-33
    Tina Ghaffari, Nariman Moradi, Elham Chamani, Zahra Ebadi, Reza Fadaei, Shahin Alizadeh-Fanalou, Sahar Yarahmadi, Soudabeh Fallah
    Current Pharmaceutical Design.2022; 28(16): 1367.     CrossRef
  • Elevated serum γ-glutamyl transferase is associated with low muscle function in adults independent of muscle mass
    Seunghyun Lee, Dawon Song, Sungjae Shin, Namki Hong, Yumie Rhee
    Nutrition.2022; 103-104: 111813.     CrossRef
  • Cross-sectional association between prolactin levels and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a retrospective analysis of patients from a single hospital in China
    Yuanyuan Zhang, Huaizhen Liu
    BMJ Open.2022; 12(10): e062252.     CrossRef
  • Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients : what do we know so far ?
    Q Binet, A Loumaye, V Preumont, J-P Thissen, M.P. Hermans, N Lanthier
    Acta Gastro Enterologica Belgica.2022; 85(2): 346.     CrossRef
  • Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
    Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
    Nutrients.2022; 14(23): 4994.     CrossRef
  • Correlation between Component Factors of Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Nurses: An Observational and Cross-Sectional Study
    Wen-Pei Chang, Yu-Pei Chang
    International Journal of Environmental Research and Public Health.2022; 19(23): 16294.     CrossRef
  • Holistic analysis of hepatosteatosis literature: a scientometric study of global hepatosteatosis publications between 1980 and 2019
    Fatih ESKİN, Engin ŞENEL
    Journal of Medicine and Palliative Care.2022; 3(4): 300.     CrossRef
  • Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
    Pengyu Yao, Yajuan Liu
    Molecules.2022; 28(1): 272.     CrossRef
  • Association of Non-Alcoholic Fatty Liver Dis-ease and Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: a Cross-Sectional Study
    Zahra Heidari, Zahra Sharafi
    Iranian South Medical Journal.2022; 25(1): 30.     CrossRef
  • Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
    Kiarash Riazi, Mark G. Swain, Stephen E. Congly, Gilaad G. Kaplan, Abdel-Aziz Shaheen
    Nutrients.2022; 14(21): 4556.     CrossRef
  • MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
    Ying-Xin Xian, Jian-Ping Weng, Fen Xu
    Chinese Medical Journal.2021; 134(1): 8.     CrossRef
  • Factors associated with elevated alanine aminotransferase in employees of a German chemical company: results of a large cross-sectional study
    Matthias Claus, Christoph Antoni, Bernd Hofmann
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model
    P. Comeglio, E. Sarchielli, S. Filippi, I. Cellai, G. Guarnieri, A. Morelli, G. Rastrelli, E. Maseroli, S. Cipriani, T. Mello, A. Galli, B. J. Bruno, K. Kim, K. Vangara, K. Papangkorn, N. Chidambaram, M. V. Patel, M. Maggi, L. Vignozzi
    Journal of Endocrinological Investigation.2021; 44(10): 2175.     CrossRef
  • Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis
    Chien-Yu Lin, Pratik Adhikary, Kun Cheng
    Advanced Drug Delivery Reviews.2021; 174: 127.     CrossRef
  • Trend for Clinical Use of Metabolic Associated Fatty Liver Disease (MAFLD)
    Hiroshi Bando
    Asploro Journal of Biomedical and Clinical Case Reports.2021; 4(2): 99.     CrossRef
  • Prediction of Cardiovascular Risk Using Nonalcoholic Fatty Liver Disease Scoring Systems
    Ye-Na Kweon, Hae-Jin Ko, A-Sol Kim, Hye-In Choi, Ji-Eun Song, Ji-Yeon Park, Sung-Min Kim, Hee-Eun Hong, Kyung-Jin Min
    Healthcare.2021; 9(7): 899.     CrossRef
  • Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice
    Yongxiang Yu, Dongru Chen, Yuhua Zhao, Jianjun Zhu, Xiaohui Dong
    International Journal of Immunopathology and Pharmacology.2021; 35: 205873842110368.     CrossRef
  • Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus
    Jaskamal Padda, Khizer Khalid, Anwar Khedr, Fahriba Tasnim, Ola A Al-Ewaidat, Ayden Charlene Cooper, Gutteridge Jean-Charles
    Cureus.2021;[Epub]     CrossRef
  • Nonalcoholic fatty liver disease and the risk of insulin-requiring gestational diabetes
    Sang Youn You, Kyungdo Han, Seung-Hawn Lee, Mee Kyoung Kim
    Diabetology & Metabolic Syndrome.2021;[Epub]     CrossRef
  • Serum syndecan‐4 is associated with nonalcoholic fatty liver disease
    Shu Jing Xia, Li Zhong Tang, Wen Hua Li, Zhao Shan Xu, Li Li Zhang, Feng Gan Cheng, Hong Xia Chen, Zi Hua Wang, Yu Cheng Luo, An Na Dai, Jian Gao Fan
    Journal of Digestive Diseases.2021; 22(9): 536.     CrossRef
  • Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
    Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
    Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
  • Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice
    Tehila Daniel, Michaella Ben-Shachar, Elyashiv Drori, Sharleen Hamad, Anna Permyakova, Elad Ben-Cnaan, Joseph Tam, Zohar Kerem, Tovit Rosenzweig
    The Journal of Nutritional Biochemistry.2021; 98: 108867.     CrossRef
  • The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease
    Sylwia Ziolkowska, Agata Binienda, Maciej Jabłkowski, Janusz Szemraj, Piotr Czarny
    International Journal of Molecular Sciences.2021; 22(20): 11128.     CrossRef
  • The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
    Hyun Min Kim, Yong-ho Lee
    Endocrinology and Metabolism.2021; 36(6): 1232.     CrossRef
  • Tip 2 Diyabet Modeli Ratların Karaciğer Dokularında Kodlanan Genlerin İfade Düzeyleri
    Lütfiye ÖZPAK, Ayfer PAZARBAŞI
    Ankara Sağlık Bilimleri Dergisi.2021; 10(1): 25.     CrossRef
  • Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
    Judith Aron-Wisnewsky, Chloé Vigliotti, Julia Witjes, Phuong Le, Adriaan G. Holleboom, Joanne Verheij, Max Nieuwdorp, Karine Clément
    Nature Reviews Gastroenterology & Hepatology.2020; 17(5): 279.     CrossRef
  • Non-alcoholic fatty liver disease and primary care physicians
    Ludovico Abenavoli, Anna C. Procopio, Milica Medić-Stojanoska, Francesco Luzza
    Minerva Gastroenterologica e Dietologica.2020;[Epub]     CrossRef
  • The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
    Hideki Fujii, Norifumi Kawada
    International Journal of Molecular Sciences.2020; 21(11): 3863.     CrossRef
  • Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway
    Yuanyuan Liu, Mengjie Wang, Wei Xu, Hongman Zhang, Weihe Qian, Xiang Li, Xingbo Cheng
    Life Sciences.2020; 241: 117086.     CrossRef
  • Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease
    Inha Jung, Hyemi Kwon, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee
    Atherosclerosis.2020; 308: 1.     CrossRef
  • The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Xueyang Zhang, Ran Bai, Yong Jia, Junwei Zong, Yongbo Wang, Yanan Dong
    International Journal of Diabetes in Developing Countries.2020; 40(4): 491.     CrossRef
  • Association between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Type 2 Diabetes Patients
    Bin Huang, Shengju Yang, Shandong Ye
    Journal of Diabetes Research.2020; 2020: 1.     CrossRef
  • The Absence of NLRP3-inflammasome Modulates Hepatic Fibrosis Progression, Lipid Metabolism, and Inflammation in KO NLRP3 Mice during Aging
    Paloma Gallego, Beatriz Castejón-Vega, José A. del Campo, Mario D. Cordero
    Cells.2020; 9(10): 2148.     CrossRef
  • Prevalence of people at risk of developing type 2 diabetes mellitus and the involvement of community pharmacies in a national screening campaign: a pioneer action in Brazil
    Cassyano J. Correr, Wendel Coura-Vital, Josélia C. Q. P. Frade, Renata C. R. M. Nascimento, Lúbia G. Nascimento, Eliete B. Pinheiro, Wesley M. Ferreira, Janice S. Reis, Karla F. S. Melo, Roberto Pontarolo, Mônica S. A. Lenzi, José V. Almeida, Hermelinda C
    Diabetology & Metabolic Syndrome.2020;[Epub]     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • Elevated TPOAb is a Strong Predictor of Autoimmune Development in Patients of Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Case–Control Study


    Chenyi Wang, Qianglong Niu, Haihong Lv, Qian Li, Yuping Ma, Jiaojiao Tan, Chunhua Liu
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4369.     CrossRef
  • Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice
    Ayala Wollman, Tehila Daniel, Tovit Rosenzweig
    Nutrients.2019; 11(12): 3044.     CrossRef
Close layer
Obesity and Metabolism
Recent Progress on Branched-Chain Amino Acids in Obesity, Diabetes, and Beyond
Md Abu Bakkar Siddik, Andrew C. Shin
Endocrinol Metab. 2019;34(3):234-246.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.234
  • 12,440 View
  • 261 Download
  • 82 Web of Science
  • 79 Crossref
AbstractAbstract PDFPubReader   ePub   

Branched-chain amino acids (BCAAs) are essential amino acids that are not synthesized in our body; thus, they need to be obtained from food. They have shown to provide many physiological and metabolic benefits such as stimulation of pancreatic insulin secretion, milk production, adipogenesis, and enhanced immune function, among others, mainly mediated by mammalian target of rapamycin (mTOR) signaling pathway. After identified as a reliable marker of obesity and type 2 diabetes in recent years, an increasing number of studies have surfaced implicating BCAAs in the pathophysiology of other diseases such as cancers, cardiovascular diseases, and even neurodegenerative disorders like Alzheimer's disease. Here we discuss the most recent progress and review studies highlighting both correlational and potentially causative role of BCAAs in the development of these disorders. Although we are just beginning to understand the intricate relationships between BCAAs and some of the most prevalent chronic diseases, current findings raise a possibility that they are linked by a similar putative mechanism.

Citations

Citations to this article as recorded by  
  • First trimester metabolomics 1H-NMR study of the urinary profile predicts gestational diabetes mellitus development in obese women
    Cristina Piras, Isabella Neri, Roberta Pintus, Antonio Noto, Elisabetta Petrella, Francesca Monari, Angelica Dessì, Vassilios Fanos, Luigi Atzori, Fabio Facchinetti
    The Journal of Maternal-Fetal & Neonatal Medicine.2024; 35(25): 8275.     CrossRef
  • Branched‐Chain Amino Acid Accumulation Fuels the Senescence‐Associated Secretory Phenotype
    Yaosi Liang, Christopher Pan, Tao Yin, Lu Wang, Xia Gao, Ergang Wang, Holly Quang, De Huang, Lianmei Tan, Kun Xiang, Yu Wang, Peter B. Alexander, Qi‐Jing Li, Tso‐Pang Yao, Zhao Zhang, Xiao‐Fan Wang
    Advanced Science.2024;[Epub]     CrossRef
  • Exploring the functional roles of small-molecule metabolites in disease research: Recent advancements in metabolomics
    Aolei Tan, Xiaoxiao Ma
    Chinese Chemical Letters.2024; 35(8): 109276.     CrossRef
  • Deficiency of BCAT2-mediated branched-chain amino acid catabolism promotes colorectal cancer development
    Zi-Ran Kang, Shanshan Jiang, Ji-Xuan Han, Yaqi Gao, Yile Xie, Jinxian Chen, Qiang Liu, Jun Yu, Xin Zhao, Jie Hong, Haoyan Chen, Ying-Xuan Chen, Huimin Chen, Jing-Yuan Fang
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(2): 166941.     CrossRef
  • Microbiome metabolite quantification methods enabling insights into human health and disease
    Jarrod Roach, Rohit Mital, Jacob J. Haffner, Nathan Colwell, Randy Coats, Horvey M. Palacios, Zongyuan Liu, Joseane L.P. Godinho, Monica Ness, Thilini Peramuna, Laura-Isobel McCall
    Methods.2024; 222: 81.     CrossRef
  • Branched-chain amino acids promote occurrence and development of cardiovascular disease dependent on triglyceride metabolism via activation of the mTOR/SREBP-1/betatrophin pathway
    Jie Zhang, Ziyu Liu, Yaojun Ni, Yang Yu, Fei Guo, Yanwen Lu, Xiaoqing Wang, Hairong Hao, Shayan Li, Pan Wei, Weinan Yu, Wen Hu
    Molecular and Cellular Endocrinology.2024; 584: 112164.     CrossRef
  • Heat stress reduces brown adipose tissue activity by exacerbating mitochondrial damage in type 2 diabetic mice
    Penghua Lai, Linlin Zhang, Yan Qiu, Jie Ren, Xue Sun, Ting Zhang, Liuyi Wang, Sijie Cheng, Sijia Liu, Hongli Zhuang, Daiwei Lu, Shaoliang Zhang, Huiqing Liang, Shaodong Chen
    Journal of Thermal Biology.2024; 119: 103799.     CrossRef
  • Unraveling Adipose Tissue Dysfunction: Molecular Mechanisms, Novel Biomarkers, and Therapeutic Targets for Liver Fat Deposition
    Marta Lopez-Yus, Carlos Hörndler, Sofia Borlan, Vanesa Bernal-Monterde, Jose M. Arbones-Mainar
    Cells.2024; 13(5): 380.     CrossRef
  • Microbial production of branched chain amino acids: Advances and perspectives
    Yanan Hao, Xuewei Pan, Jiajia You, Guomin Li, Meijuan Xu, Zhiming Rao
    Bioresource Technology.2024; 397: 130502.     CrossRef
  • Maintenance of the branched-chain amino acid transporter LAT1 counteracts myotube atrophy following chemotherapy
    Stephen Mora, Olasunkanmi A. J. Adegoke
    American Journal of Physiology-Cell Physiology.2024; 326(3): C866.     CrossRef
  • Metabolomics of Mice with Type 2 Diabetes and Nonalcoholic Fatty Liver Treated by Acupuncture
    Yihui Guo, Liying Zhang, Mengyuan Li, Linan Lin, Fuyu Xue, Wanning Gao, Xiaoru Xu, Haipeng Huang, Abdelilah Arredouani
    International Journal of Endocrinology.2024; 2024: 1.     CrossRef
  • The effectiveness of low-calorie dietary interventions in managing obesity in patients. A review
    Ekaterina A. Troshina, Ksenia A. Komshilova, Natalia V. Silina, Ekaterina V. Ershova, Fatima K. Dzgoeva
    Consilium Medicum.2024; 26(4): 251.     CrossRef
  • Duality of Branched-Chain Amino Acids in Chronic Cardiovascular Disease: Potential Biomarkers versus Active Pathophysiological Promoters
    Daniela Maria Tanase, Emilia Valasciuc, Claudia Florida Costea, Dragos Viorel Scripcariu, Anca Ouatu, Loredana Liliana Hurjui, Claudia Cristina Tarniceriu, Diana Elena Floria, Manuela Ciocoiu, Livia Genoveva Baroi, Mariana Floria
    Nutrients.2024; 16(12): 1972.     CrossRef
  • Metabolic Signatures Elucidate the Effect of Body Mass Index on Type 2 Diabetes
    Qiuling Dong, Sidra Sidra, Christian Gieger, Rui Wang-Sattler, Wolfgang Rathmann, Cornelia Prehn, Jerzy Adamski, Wolfgang Koenig, Annette Peters, Harald Grallert, Sapna Sharma
    Metabolites.2023; 13(2): 227.     CrossRef
  • The Preventive Effect of Exercise and Oral Branched-Chain Amino Acid Supplementation on Obesity-Induced Brain Changes in Ldlr−/−.Leiden Mice
    Klara J. Lohkamp, Anita M. van den Hoek, Gemma Solé-Guardia, Maria Lisovets, Talissa Alves Hoffmann, Konstantina Velanaki, Bram Geenen, Vivienne Verweij, Martine C. Morrison, Robert Kleemann, Maximilian Wiesmann, Amanda J. Kiliaan
    Nutrients.2023; 15(7): 1716.     CrossRef
  • The Crosstalk between Gut Microbiota and White Adipose Tissue Mitochondria in Obesity
    Luca Colangeli, David Israel Escobar Marcillo, Valeria Simonelli, Egidio Iorio, Tommaso Rinaldi, Paolo Sbraccia, Paola Fortini, Valeria Guglielmi
    Nutrients.2023; 15(7): 1723.     CrossRef
  • Prebiotic and Probiotic Modulation of the Microbiota–Gut–Brain Axis in Depression
    Daniel E. Radford-Smith, Daniel C. Anthony
    Nutrients.2023; 15(8): 1880.     CrossRef
  • Machine learning model to predict obesity using gut metabolite and brain microstructure data
    Vadim Osadchiy, Roshan Bal, Emeran A. Mayer, Rama Kunapuli, Tien Dong, Priten Vora, Danny Petrasek, Cathy Liu, Jean Stains, Arpana Gupta
    Scientific Reports.2023;[Epub]     CrossRef
  • Insulin Resistance and Impaired Branched-Chain Amino Acid Metabolism in Alzheimer’s Disease
    Rui Liu, Lei Zhang, Hao You
    Journal of Alzheimer's Disease.2023; 93(3): 847.     CrossRef
  • Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
    Rexiati Ruze, Tiantong Liu, Xi Zou, Jianlu Song, Yuan Chen, Ruiyuan Xu, Xinpeng Yin, Qiang Xu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Crosstalk between arginine, glutamine, and the branched chain amino acid metabolism in the tumor microenvironment
    Tanner J. Wetzel, Sheila C. Erfan, Lucas D. Figueroa, Leighton M. Wheeler, Elitsa A. Ananieva
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Stachydrine, N‐acetylornithine and trimethylamine N‐oxide levels as candidate milk biomarkers of maternal consumption of an obesogenic diet during lactation
    Pedro Castillo, Ondrej Kuda, Jan Kopecky, Catalina Amadora Pomar, Andreu Palou, Mariona Palou, Catalina Picó
    BioFactors.2023; 49(5): 1022.     CrossRef
  • Biofunctionalization of natural extracts, trends in biological activity and kinetic release
    Abraham Osiris Martínez-Olivo, Víctor Manuel Zamora-Gasga, Luis Medina-Torres, Alejandro Pérez-Larios, Sonia Guadalupe Sáyago-Ayerdi, Jorge Alberto Sánchez-Burgos
    Advances in Colloid and Interface Science.2023; 318: 102938.     CrossRef
  • Muscle Traits, Sarcopenia, and Sarcopenic Obesity: A Vitamin D Mendelian Randomization Study
    Joshua P. Sutherland, Ang Zhou, Elina Hyppönen
    Nutrients.2023; 15(12): 2703.     CrossRef
  • Bioactive Ingredients in Traditional Fermented Food Condiments: Emerging Products for Prevention and Treatment of Obesity and Type 2 Diabetes
    Alphonse Laya, Honoré Wangso, Iva Fernandes, Raphaël Djakba, Joana Oliveira, Eugenia Carvalho, Wen yi Kang
    Journal of Food Quality.2023; 2023: 1.     CrossRef
  • Sex related differences in muscle health and metabolism in chronic obstructive pulmonary disease
    Mariëlle P.K.J. Engelen, Sarah K. Kirschner, Kimberly S. Coyle, David Argyelan, Gabriel Neal, Srinivasan Dasarathy, Nicolaas E.P. Deutz
    Clinical Nutrition.2023; 42(9): 1737.     CrossRef
  • Depiction of Branched-Chain Amino Acids (BCAAs) in Diabetes with a Focus on Diabetic Microvascular Complications
    Daniela Maria Tanase, Evelina Maria Gosav, Tina Botoc, Mariana Floria, Claudia Cristina Tarniceriu, Minela Aida Maranduca, Anca Haisan, Andrei Ionut Cucu, Ciprian Rezus, Claudia Florida Costea
    Journal of Clinical Medicine.2023; 12(18): 6053.     CrossRef
  • Genetic and Lifestyle-Related Factors Influencing Serum Hyper-Propionylcarnitine Concentrations and Their Association with Metabolic Syndrome and Cardiovascular Disease Risk
    Yong-Hwa Lee, Sunmin Park
    International Journal of Molecular Sciences.2023; 24(21): 15810.     CrossRef
  • Relationship between Components, Intestinal Microbiota, and Mechanism of Hypoglycemic Effect of the Saggy Ink Cap Medicinal Mushroom (Coprinus Comatus, Agaricomycetes): A Review
    Wei Wang, Min Sun, Jinyan Yu, Xumin Ma, Chunchao Han
    International Journal of Medicinal Mushrooms.2023; 25(12): 81.     CrossRef
  • High-protein diet with excess leucine prevents inactivity-induced insulin resistance in women
    Alessandro Mangogna, Filippo Giorgio Di Girolamo, Nicola Fiotti, Pierandrea Vinci, Matteo Landolfo, Filippo Mearelli, Gianni Biolo
    Clinical Nutrition.2023; 42(12): 2578.     CrossRef
  • Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer
    Aliya Lakhani, Da Hyun Kang, Yea Eun Kang, Junyoung O. Park
    Endocrinology and Metabolism.2023; 38(6): 619.     CrossRef
  • Dietary intake of branched-chain amino acids in relation to general and abdominal obesity
    Farzaneh Asoudeh, Asma Salari-Moghaddam, Ammar Hassanzadeh Keshteli, Ahmad Esmaillzadeh, Peyman Adibi
    Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.2022; 27(4): 1303.     CrossRef
  • Tea polyphenol – gut microbiota interactions: hints on improving the metabolic syndrome in a multi-element and multi-target manner
    Hui Ma, Yaozhong Hu, Bowei Zhang, Zeping Shao, Eugeni Roura, Shuo Wang
    Food Science and Human Wellness.2022; 11(1): 11.     CrossRef
  • Exogenous isoleucine can confer browning resistance on fresh-cut potato by suppressing polyphenol oxidase activity and improving the antioxidant capacity
    Zan Meng, Tong Wang, Aman Ullah Malik, Qingguo Wang
    Postharvest Biology and Technology.2022; 184: 111772.     CrossRef
  • Impact of thermal treatment and fermentation by lactic acid bacteria on sorghum metabolite changes, their antioxidant and antidiabetic activities
    Fred Kwame Ofosu, Fazle Elahi, Eric Banan-Mwine Daliri, Sang-Ik Han, Deog-Hwan Oh
    Food Bioscience.2022; 45: 101502.     CrossRef
  • Infant intakes of human milk branched chain amino acids are negatively associated with infant growth and influenced by maternal body mass index
    Jessica L. Saben, Clark R. Sims, Lindsay Pack, Renny Lan, Elisabet Børsheim, Aline Andres
    Pediatric Obesity.2022;[Epub]     CrossRef
  • Roux-En-Y Gastric Bypass (RYGB) Surgery during High Liquid Sucrose Diet Leads to Gut Microbiota-Related Systematic Alterations
    Laimdota Zizmare, Christina N. Boyle, Sabrina Buss, Sandrine Louis, Laura Kuebler, Ketki Mulay, Ralf Krüger, Lara Steinhauer, Isabelle Mack, Manuel Rodriguez Gomez, Kristina Herfert, Yvonne Ritze, Christoph Trautwein
    International Journal of Molecular Sciences.2022; 23(3): 1126.     CrossRef
  • Omics Analyses of Intestinal Microbiota and Hypothalamus Clock Genes in Circadian Disturbance Model Mice Fed with Green Tea Polyphenols
    Yuting Zhang, Lu Cheng, Yanan Liu, Ruilin Zhang, Zufang Wu, Kejun Cheng, Xin Zhang
    Journal of Agricultural and Food Chemistry.2022; 70(6): 1890.     CrossRef
  • Age, Sex, Body Mass Index, Diet and Menopause Related Metabolites in a Large Homogeneous Alpine Cohort
    Vinicius Verri Hernandes, Nikola Dordevic, Essi Marjatta Hantikainen, Baldur Bragi Sigurdsson, Sigurður Vidir Smárason, Vanessa Garcia-Larsen, Martin Gögele, Giulia Caprioli, Ilaria Bozzolan, Peter P. Pramstaller, Johannes Rainer
    Metabolites.2022; 12(3): 205.     CrossRef
  • α-ketoisocaproic acid promotes ER stress through impairment of autophagy, thereby provoking lipid accumulation and insulin resistance in murine preadipocytes
    Tae Jun Park, Seung Yeon Park, Hyun Jung Lee, A.M. Abd El-Aty, Ji Hoon Jeong, Tae Woo Jung
    Biochemical and Biophysical Research Communications.2022; 603: 109.     CrossRef
  • The associations of serum valine with mild cognitive impairment and Alzheimer’s disease
    Yong-lan Xiong, Joseph Therriault, Shu-jiang Ren, Xiao-jun Jing, Hua Zhang
    Aging Clinical and Experimental Research.2022; 34(8): 1807.     CrossRef
  • The Critical Role of the Branched Chain Amino Acids (BCAAs) Catabolism-Regulating Enzymes, Branched-Chain Aminotransferase (BCAT) and Branched-Chain α-Keto Acid Dehydrogenase (BCKD), in Human Pathophysiology
    Aikaterini Dimou, Vasilis Tsimihodimos, Eleni Bairaktari
    International Journal of Molecular Sciences.2022; 23(7): 4022.     CrossRef
  • Obesity, exercise training, and BCAA supplementation: All that glitters (may not be) gold
    Stephen J. Carter, Emily B. Long, Cydne A. Perry
    Obesity.2022; 30(6): 1139.     CrossRef
  • Effects of serum branched-chain amino acids on nonalcoholic fatty liver disease and subsequent cardiovascular disease
    Fei Guo, Rui Chen, Linghui Kong, Pan Wei, Ziyu Liu, Xiaoqing Wang, Hairong Hao, Yanwen Lu, Wen Hu
    Hepatology International.2022; 16(6): 1424.     CrossRef
  • Advances in multi-omics study of biomarkers of glycolipid metabolism disorder
    Xinyi Fang, Runyu Miao, Jiahua Wei, Haoran Wu, Jiaxing Tian
    Computational and Structural Biotechnology Journal.2022; 20: 5935.     CrossRef
  • Targeted Metabolomics Revealed a Sex-Dependent Signature for Metabolic Syndrome in the Mexican Population
    Berenice Palacios-González, Guadalupe León-Reyes, Berenice Rivera-Paredez, Isabel Ibarra-González, Marcela Vela-Amieva, Yvonne N. Flores, Samuel Canizales-Quinteros, Jorge Salmerón, Rafael Velázquez-Cruz
    Nutrients.2022; 14(18): 3678.     CrossRef
  • Case report: NAFLD and maple syrup urine disease: Is there an interplay between branched-chain amino acids and fructose consumption?
    Helena Moreira-Silva, Sandra Ferreira, Manuela Almeida, Isabel Gonçalves, Maria Augusta Cipriano, J. R. Vizcaíno, Ermelinda Santos-Silva, Esmeralda Gomes-Martins
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia
    Xi Xu, Jian Wang, Tong Tong, Wenwen Zhang, Jin Wang, Weiwei Ma, Shunqing Wang, Dunhua Zhou, Jun Wu, Linjia Jiang, Meng Zhao
    Haematologica.2022; 107(10): 2344.     CrossRef
  • Effect of dietary protein content shift on aging in elderly rats by comprehensive quantitative score and metabolomics analysis
    Wenxuan Zheng, Ruiding Li, Yang Zhou, Fengcui Shi, Yao Song, Yanting Liao, Fan Zhou, Xiaohua Zheng, Jingwen Lv, Quanyang Li
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Caloric restriction improves glycaemic control without reducing plasma branched-chain amino acids or keto-acids in obese men
    M. H. Sayda, M. H. Abdul Aziz, N. Gharahdaghi, D. J. Wilkinson, P. L. Greenhaff, B. E. Phillips, K. Smith, I. Idris, P. J. Atherton
    Scientific Reports.2022;[Epub]     CrossRef
  • Dietary Protein and Amino Acid Deficiency Inhibit Pancreatic Digestive Enzyme mRNA Translation by Multiple Mechanisms
    Maria Dolors Sans, Stephen J. Crozier, Nancy L. Vogel, Louis G. D’Alecy, John A. Williams
    Cellular and Molecular Gastroenterology and Hepatology.2021; 11(1): 99.     CrossRef
  • Isoleucine increases muscle mass through promoting myogenesis and intramyocellular fat deposition
    Shuge Liu, Yunmei Sun, Rui Zhao, Yingqian Wang, Wanrong Zhang, Weijun Pang
    Food & Function.2021; 12(1): 144.     CrossRef
  • Serum metabolomics study of women with different annual decline rates of anti-Müllerian hormone: an untargeted gas chromatography–mass spectrometry-based study
    Nazanin Moslehi, Parvin Mirmiran, Rezvan Marzbani, Hassan Rezadoost, Mehdi Mirzaie, Fereidoun Azizi, Fahimeh Ramezani Tehrani
    Human Reproduction.2021; 36(3): 721.     CrossRef
  • Amino acid sensing pathway: A major check point in the pathogenesis of obesity and COVID‐19
    Aradhana Mariam Philips, Nooruddin Khan
    Obesity Reviews.2021;[Epub]     CrossRef
  • The chemical mechanisms of the enzymes in the branched-chain amino acids biosynthetic pathway and their applications
    Yan-Fei Liang, Zi-Xian Long, Ya-Jian Zhang, Cai-Yun Luo, Le-Tian Yan, Wen-Yun Gao, Heng Li
    Biochimie.2021; 184: 72.     CrossRef
  • Plasma Metabolomic Profiling in 1391 Subjects with Overweight and Obesity from the SPHERE Study
    Gianfranco Frigerio, Chiara Favero, Diego Savino, Rosa Mercadante, Benedetta Albetti, Laura Dioni, Luisella Vigna, Valentina Bollati, Angela Cecilia Pesatori, Silvia Fustinoni
    Metabolites.2021; 11(4): 194.     CrossRef
  • Sarcopenic Obesity and Amino Acids: Concord Health and Ageing in Men Project
    David G Le Couteur, David J Handelsman, Fiona Stanaway, Louise M Waite, Fiona M Blyth, Vasi Naganathan, Robert G Cumming, Vasant Hirani, Rafael de Cabo
    The Journals of Gerontology: Series A.2021; 76(6): 1000.     CrossRef
  • Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the European Prospective Investigation into Cancer and Nutrition
    Nathalie Kliemann, Vivian Viallon, Neil Murphy, Rebecca J. Beeken, Joseph A. Rothwell, Sabina Rinaldi, Nada Assi, Eline H. van Roekel, Julie A. Schmidt, Kristin Benjaminsen Borch, Claudia Agnoli, Ann H. Rosendahl, Hanna Sartor, José María Huerta, Anne Tjø
    BMC Medicine.2021;[Epub]     CrossRef
  • Plasma Amino Acids and Residual Hypertriglyceridemia in Diabetic Patients Under Statins: Two Independent Cross-Sectional Hospital-Based Cohorts
    Shuang Wang, Yun-Feng Cao, Xiao-Yu Sun, Mo Hong, Zhong-Ze Fang, Hui-Huan Luo, Huan Sun, Ping Yang
    Frontiers in Cardiovascular Medicine.2021;[Epub]     CrossRef
  • Identification of Metabolic Phenotypes in Young Adults with Obesity by 1H NMR Metabolomics of Blood Serum
    Khin Thandar Htun, Jie Pan, Duanghathai Pasanta, Montree Tungjai, Chatchanok Udomtanakunchai, Sirirat Chancharunee, Siriprapa Kaewjaeng, Hong Joo Kim, Jakrapong Kaewkhao, Suchart Kothan
    Life.2021; 11(6): 574.     CrossRef
  • A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach
    Lina A. Dahabiyeh, Muhammad Mujammami, Tawfiq Arafat, Hicham Benabdelkamel, Assim A. Alfadda, Anas M. Abdel Rahman
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Branched-chain Amino Acids: Catabolism in Skeletal Muscle and Implications for Muscle and Whole-body Metabolism
    Gagandeep Mann, Stephen Mora, Glory Madu, Olasunkanmi A. J. Adegoke
    Frontiers in Physiology.2021;[Epub]     CrossRef
  • Identification of TBX15 as an adipose master trans regulator of abdominal obesity genes
    David Z. Pan, Zong Miao, Caroline Comenho, Sandhya Rajkumar, Amogha Koka, Seung Hyuk T. Lee, Marcus Alvarez, Dorota Kaminska, Arthur Ko, Janet S. Sinsheimer, Karen L. Mohlke, Nicholas Mancuso, Linda Liliana Muñoz-Hernandez, Miguel Herrera-Hernandez, Maria
    Genome Medicine.2021;[Epub]     CrossRef
  • Antidiabetic Effect of Noodles Containing Fermented Lettuce Extracts
    Soon Yeon Jeong, Eunjin Kim, Ming Zhang, Yun-Seong Lee, Byeongjun Ji, Sun-Hee Lee, Yu Eun Cheong, Soon-Il Yun, Young-Soo Kim, Kyoung Heon Kim, Min Sun Kim, Hyun Soo Chun, Sooah Kim
    Metabolites.2021; 11(8): 520.     CrossRef
  • Targeted and Untargeted Mass Spectrometry Reveals the Impact of High-Fat Diet on Peripheral Amino Acid Regulation in a Mouse Model of Alzheimer’s Disease
    Amelia L. Taylor, Don E. Davis, Simona G. Codreanu, Fiona E. Harrison, Stacy D. Sherrod, John A. McLean
    Journal of Proteome Research.2021; 20(9): 4405.     CrossRef
  • The Association of 9 Amino Acids With Cardiovascular Events in Finnish Men in a 12-Year Follow-up Study
    Raimo Jauhiainen, Jagadish Vangipurapu, Annamaria Laakso, Teemu Kuulasmaa, Johanna Kuusisto, Markku Laakso
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(12): 3448.     CrossRef
  • Serum Metabolite Profile Associated with Sex-Dependent Visceral Adiposity Index and Low Bone Mineral Density in a Mexican Population
    Berenice Palacios-González, Guadalupe León-Reyes, Berenice Rivera-Paredez, Isabel Ibarra-González, Marcela Vela-Amieva, Yvonne N. Flores, Samuel Canizales-Quinteros, Jorge Salmerón, Rafael Velázquez-Cruz
    Metabolites.2021; 11(9): 604.     CrossRef
  • Branched chain amino acids—friend or foe in the control of energy substrate turnover and insulin sensitivity?
    Elżbieta Supruniuk, Ewa Żebrowska, Adrian Chabowski
    Critical Reviews in Food Science and Nutrition.2021; : 1.     CrossRef
  • Diet Effects on Cerebrospinal Fluid Amino Acids Levels in Adults with Normal Cognition and Mild Cognitive Impairment
    Kate J. Russin, K. Sreekumaran Nair, Thomas J. Montine, Laura D. Baker, Suzanne Craft
    Journal of Alzheimer's Disease.2021; 84(2): 843.     CrossRef
  • QSHY Granules Promote White Adipose Tissue Browning and Correct BCAAs Metabolic Disorder in NAFLD Mice
    Binbin Zhang, Mingzhu Ni, Xiaojing Li, Qiaohong Liu, Yiyang Hu, Yu Zhao
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 4241.     CrossRef
  • The Changes in Endogenous Metabolites in Hyperlipidemic Rats Treated with Herbal Mixture Containing Lemon, Apple Cider, Garlic, Ginger, and Honey
    Azliana Abu Bakar Sajak, Azrina Azlan, Faridah Abas, Hazilawati Hamzah
    Nutrients.2021; 13(10): 3573.     CrossRef
  • Integration of Transcriptome and Metabolome Provides Unique Insights to Pathways Associated With Obese Breast Cancer Patients
    Mohammed A. Hassan, Kaltoom Al-Sakkaf, Mohammed Razeeth Shait Mohammed, Ashraf Dallol, Jaudah Al-Maghrabi, Alia Aldahlawi, Sawsan Ashoor, Mabrouka Maamra, Jiannis Ragoussis, Wei Wu, Mohammad Imran Khan, Abdulrahman L. Al-Malki, Hani Choudhry
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Omics Biomarkers in Obesity: Novel Etiological Insights and Targets for Precision Prevention
    Krasimira Aleksandrova, Caue Egea Rodrigues, Anna Floegel, Wolfgang Ahrens
    Current Obesity Reports.2020; 9(3): 219.     CrossRef
  • Why Are Branched-Chain Amino Acids Increased in Starvation and Diabetes?
    Milan Holeček
    Nutrients.2020; 12(10): 3087.     CrossRef
  • Differential gene signature in adipose tissue depots of growth hormone transgenic mice
    Silvana Duran‐Ortiz, Jonathan A. Young, Adam Jara, Elizabeth A. Jensen, Reetobrata Basu, Edward O. List, Yanrong Qian, John J. Kopchick, Darlene E. Berryman
    Journal of Neuroendocrinology.2020;[Epub]     CrossRef
  • Prognostic Role of Serum Amino Acids in Head and Neck Cancer
    Gabriella Cadoni, Luca Giraldi, Carlo Chiarla, Jacopo Gervasoni, Silvia Persichilli, Aniello Primiano, Stefano Settimi, Jacopo Galli, Gaetano Paludetti, Dario Arzani, Stefania Boccia, Ivo Giovannini, Giovanni Almadori, Leigh A. Madden
    Disease Markers.2020; 2020: 1.     CrossRef
  • Lipid changes in the metabolome of a single case study with maple syrup urine disease (MSUD) after five days of improved diet adherence of controlled branched-chain amino acids (BCAA)
    Teresa D. Douglas, L. Kristin Newby, Julie Eckstrand, Douglas Wixted, Rani H. Singh
    Molecular Genetics and Metabolism Reports.2020; 25: 100651.     CrossRef
  • Branched chain amino acids, aging and age-related health
    David G. Le Couteur, Samantha M. Solon-Biet, Victoria C. Cogger, Rosilene Ribeiro, Rafael de Cabo, David Raubenheimer, Gregory J. Cooney, Stephen J. Simpson
    Ageing Research Reviews.2020; 64: 101198.     CrossRef
  • Branched-chain ketoacid overload inhibits insulin action in the muscle
    Dipsikha Biswas, Khoi T. Dao, Angella Mercer, Andrew M. Cowie, Luke Duffley, Yassine El Hiani, Petra C. Kienesberger, Thomas Pulinilkunnil
    Journal of Biological Chemistry.2020; 295(46): 15597.     CrossRef
Close layer
Diabetes
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinol Metab. 2019;34(3):247-262.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.247
  • 12,793 View
  • 460 Download
  • 64 Web of Science
  • 69 Crossref
AbstractAbstract PDFPubReader   ePub   

Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel glucose-lowering therapies that have been shown to induce clinically significant reductions in body weight. However, this weight loss may not be attributed solely to fat mass (FM). Given the importance of skeletal muscle and lean body mass (LBM) on cardio-metabolic health and physical function, we reviewed the available literature reporting the effects of GLP-1RAs and SGLT2is on body composition. Results demonstrate that, in most circumstances, the weight loss associated with both therapies predominantly comprises a reduction in FM, although significant heterogeneity exists between studies. In over half of the studies identified, the proportion of LBM reduction ranged between 20% and 50% of total weight lost, which is consistent with diet-induced weight loss and bariatric surgery. No clear differences existed between GLP-1RAs and SGLT2is. Consequently, the loss of LBM and skeletal muscle associated with weight loss induced by GLP-1RAs and SGLT2is warrants attention. Strategies to preserve skeletal muscle and improve physical function, for example through structured exercise, are of great importance.

Citations

Citations to this article as recorded by  
  • Drug‐related sarcopenia as a secondary sarcopenia
    Masafumi Kuzuya
    Geriatrics & Gerontology International.2024; 24(2): 195.     CrossRef
  • Exercise induces tissue-specific adaptations to enhance cardiometabolic health
    Stephen P. Ashcroft, Ben Stocks, Brendan Egan, Juleen R. Zierath
    Cell Metabolism.2024; 36(2): 278.     CrossRef
  • Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes
    Rieko Kanai, Sachiho Kinoshita, Izumi Kanbe, Mariko Sameda, Shuhei Yamaoka, Osamu Horikawa, Yasuhiro Watanabe, Ichiro Tatsuno, Kohji Shirai, Takashi Oshiro, Atsuhito Saiki
    Obesity Pillars.2024; 9: 100098.     CrossRef
  • Twenty‐four‐hour physical behaviour profiles across type 2 diabetes mellitus subtypes
    Joseph Henson, Aikaterina Tziannou, Alex V. Rowlands, Charlotte L. Edwardson, Andrew P. Hall, Melanie J. Davies, Thomas Yates
    Diabetes, Obesity and Metabolism.2024; 26(4): 1355.     CrossRef
  • The Current Landscape of Pharmacotherapies for Sarcopenia
    Gulistan Bahat, Serdar Ozkok
    Drugs & Aging.2024; 41(2): 83.     CrossRef
  • Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
    ELISSA DRIGGIN, PARAG GOYAL
    Journal of Cardiac Failure.2024; 30(4): 610.     CrossRef
  • Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?
    Daniel Lee, Jacqueline Capeau
    AIDS.2024; 38(4): 603.     CrossRef
  • Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
    Xin‐Hui Pan, Bryan Tan, Yip Han Chin, Ethan Cheng Zhe Lee, Gwyneth Kong, Bryan Chong, Martin Kueh, Chin Meng Khoo, Anurag Mehta, Priyanka Majety, Gowtham R. Grandhi, Georgios K. Dimitriadis, Roger Foo, Nicholas W. S. Chew, Carel W. Le Roux, Mamas A. Mamas
    Obesity.2024; 32(5): 840.     CrossRef
  • Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction
    David Ni, Peter Kokkinos, Eric S Nylen
    Military Medicine.2024;[Epub]     CrossRef
  • Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
    Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, Timo D. Müller
    Diabetes Therapy.2024; 15(5): 1069.     CrossRef
  • GPR75: A Newly Identified Receptor for Targeted Intervention in the Treatment of Obesity and Metabolic Syndrome
    Michael L. Fragner, Manish A. Parikh, Kaedrea A. Jackson, Michal Laniado Schwartzman, William H. Frishman, Stephen J. Peterson
    Cardiology in Review.2024;[Epub]     CrossRef
  • The effects of myosteatosis on skeletal muscle function in older adults
    Kathleen Dondero, Ben Friedman, Julie Rekant, Rian Landers‐Ramos, Odessa Addison
    Physiological Reports.2024;[Epub]     CrossRef
  • Preservation of healthy lean body mass and function during weight loss
    T. J. Wilkinson, D. Papamargaritis, J. A. King, J. A. Sargeant, C. Sutcliffe, L. A. Baker, S. Taheri, T. Yates, M. J. Davies
    Clinical Obesity.2024;[Epub]     CrossRef
  • The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis
    Emanuela Talamonti, Jelena Davegardh, Anastasia Kalinovich, Sten M.M. van Beek, Nodi Dehvari, Carina Halleskog, Hamza M. Bokhari, Dana S. Hutchinson, Seungmin Ham, Laura J. Humphrys, Nicola C. Dijon, Aikaterini Motso, Anna Sandstrom, Evelyn Zacharewicz, I
    Molecular Metabolism.2024; 85: 101931.     CrossRef
  • Core Trainee Prize Winner: Weight loss drugs: their role and potential future in orthopaedic surgery
    Tom Doyle
    Bone & Joint 360.2024; 13(3): 12.     CrossRef
  • Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review
    Guillaume Mahé, Victor Aboyans, Emmanuel Cosson, Kamel Mohammedi, Gabrielle Sarlon-Bartoli, Damien Lanéelle, Tristan Mirault, Patrice Darmon
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies
    Ian J. Neeland, Jennifer Linge, Andreas L. Birkenfeld
    Diabetes, Obesity and Metabolism.2024;[Epub]     CrossRef
  • Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice
    Paola Pantanetti, Giovanni Cangelosi, Sara Alberti, Sandra Di Marco, Grazia Michetti, Gianluca Cerasoli, Marco Di Giacinti, Silvia Coacci, Nadia Francucci, Fabio Petrelli, Giuseppe Ambrosio, Roberto Grinta
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus
    Oluwaseun Anyiam, Bethan Phillips, Katie Quinn, Daniel Wilkinson, Kenneth Smith, Philip Atherton, Iskandar Idris
    Clinical Nutrition.2024; 43(8): 1907.     CrossRef
  • Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial
    Shinsuke Takeuchi, Takashi Kohno, Ayumi Goda, Yasuyuki Shiraishi, Mike Saji, Yuji Nagatomo, Toshikazu D. Tanaka, Makoto Takei, Shintaro Nakano, Kyoko Soejima, Shun Kohsaka, Tsutomu Yoshikawa
    International Journal of Cardiology.2023; 370: 263.     CrossRef
  • Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
    Sara Santini, Nathalie Vionnet, Jérôme Pasquier, Elena Gonzalez‐Rodriguez, Montserrat Fraga, Nelly Pitteloud, Lucie Favre
    Obesity.2023; 31(1): 74.     CrossRef
  • Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
    Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
    Diabetes, Obesity and Metabolism.2023; 25(4): 901.     CrossRef
  • The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
    Rishi Jobanputra, Jack A. Sargeant, Abdullah Almaqhawi, Ehtasham Ahmad, Franciskos Arsenyadis, David R. Webb, Louisa Y. Herring, Kamlesh Khunti, Melanie J. Davies, Thomas Yates
    Obesity Reviews.2023;[Epub]     CrossRef
  • Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
    Rasmus M. Sandsdal, Christian R. Juhl, Simon B. K. Jensen, Julie R. Lundgren, Charlotte Janus, Martin B. Blond, Mads Rosenkilde, Adrian F. Bogh, Lasse Gliemann, Jens-Erik B. Jensen, Charalambos Antoniades, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials
    Ehtasham Ahmad, Franciskos Arsenyadis, Abdullah Almaqhawi, Mary Barker, Rishi Jobanputra, Jack A. Sargeant, David R. Webb, Thomas Yates, Melanie J. Davies
    Diabetic Medicine.2023;[Epub]     CrossRef
  • Cancer cachexia as a blueprint for treating obesity
    Nikolai P. Jaschke, Tilman D. Rachner
    Trends in Endocrinology & Metabolism.2023; 34(7): 395.     CrossRef
  • The sun is rising on a new era of pharmacotherapy for obesity: some words of caution
    Peter N. Benotti, Bruce R. Bistrian
    Surgery for Obesity and Related Diseases.2023; 19(9): 1075.     CrossRef
  • Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
    Cody Rutledge, Angela Enriquez, Kevin Redding, Mabel Lopez, Steven Mullett, Stacy L. Gelhaus, Michael Jurczak, Eric Goetzman, Brett A. Kaufman
    Cardiovascular Drugs and Therapy.2023;[Epub]     CrossRef
  • Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Sha Zhang, Zhan Qi, Yidong Wang, Danfei Song, Deqiu Zhu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Cysteine‐lowering treatment with mesna against obesity: Proof of concept and results from a human phase I, dose‐finding study
    Kathrine J. Vinknes, Thomas Olsen, Hasse Khiabani Zaré, Nasser E. Bastani, Emma Stolt, Anja F. Dahl, Roger D. Cox, Helga Refsum, Kjetil Retterstøl, Anders Åsberg, Amany Elshorbagy
    Diabetes, Obesity and Metabolism.2023; 25(11): 3161.     CrossRef
  • Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review
    Miles D. Witham, Antoneta Granic, Ewan Pearson, Sian M. Robinson, Avan A. Sayer
    Drugs & Aging.2023; 40(8): 703.     CrossRef
  • Introduction to the dietary management of obesity in adults
    Vivian Lee
    Clinical Medicine.2023; 23(4): 304.     CrossRef
  • Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)
    Daisuke Yabe, Kosuke Shiki, Gosuke Homma, Thomas Meinicke, Yuji Ogura, Yutaka Seino
    Diabetes, Obesity and Metabolism.2023; 25(12): 3538.     CrossRef
  • Independent Link Between Use of Mineralocorticoid Receptor Antagonists and Muscle Wasting in Heart Failure Patients Not Receiving Renin-Angiotensin System Inhibitors
    Ryo Numazawa, Satoshi Katano, Toshiyuki Yano, Ryohei Nagaoka, Katsuhiko Ohori, Hidemichi Kouzu, Suguru Honma, Yusuke Fujisawa, Kotaro Yamano, Arata Osanami, Masayuki Koyama, Akiyoshi Hashimoto, Masato Furuhashi
    Circulation Journal.2023; 88(1): 10.     CrossRef
  • Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
    Baris Afsar, Rengin Elsurer Afsar
    Clinical Nutrition.2023; 42(12): 2338.     CrossRef
  • Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
    Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
    Soodeh Jahangiri, Mojtaba Malek, Sanjay Kalra, Mohammad E. Khamseh
    Diabetes Therapy.2023; 14(12): 2015.     CrossRef
  • Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Chengdong Xia, Yufeng Han, Chunhui Yin, Ruyue Geng, Zhenfei Liu, Yongle Du, Mingkun Yu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
    Thomas A. Wadden, Ariana M. Chao, Molly Moore, Jena S. Tronieri, Adam Gilden, Anastassia Amaro, Sharon Leonard, John M. Jakicic
    Current Obesity Reports.2023; 12(4): 453.     CrossRef
  • Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
    Giuseppe Lisco, Olga Eugenia Disoteo, Anna De Tullio, Vincenzo De Geronimo, Vito Angelo Giagulli, Fabio Monzani, Emilio Jirillo, Renato Cozzi, Edoardo Guastamacchia, Giovanni De Pergola, Vincenzo Triggiani
    Nutrients.2023; 16(1): 63.     CrossRef
  • Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
    Sabine Kahl, Jennifer Pützer, Michael Roden
    Seminars in Liver Disease.2022; 42(01): 048.     CrossRef
  • Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
    Yu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru
    Journal of Cardiac Failure.2022; 28(1): 56.     CrossRef
  • Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
    Shohei Yamada, Yuji Ogura, Kazuho Inoue, Jun Tanabe, Takeshi Sugaya, Keiichi Ohata, Yoshio Nagai, Yasunori Natsuki, Seiko Hoshino, Shiika Watanabe, Daisuke Ichikawa, Kenjiro Kimura, Yugo Shibagaki, Atsuko Kamijo-Ikemori
    Molecular and Cellular Endocrinology.2022; 539: 111472.     CrossRef
  • Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
    Olfa Khalifa, Neyla S. AL-Akl, Khaoula Errafii, Abdelilah Arredouani
    Scientific Reports.2022;[Epub]     CrossRef
  • Body composition changes at 12 months following different surgical weight loss interventions in adults with obesity: A systematic review and meta‐analysis of randomized control trials
    Amy Sylivris, Jakub Mesinovic, David Scott, Paul Jansons
    Obesity Reviews.2022;[Epub]     CrossRef
  • Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
    Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
    Expert Opinion on Drug Safety.2022; 21(10): 1315.     CrossRef
  • Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
    Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno, Daisuke Nitta
    Expert Opinion on Drug Safety.2022; 21(11): 1411.     CrossRef
  • Le risque de dénutrition chez le sujet âgé diabétique : une limite à l’utilisation des « nouvelles » classes thérapeutiques ?
    Lyse Bordier, Jean Doucet, Bernard Bauduceau
    Médecine des Maladies Métaboliques.2022; 16(5): 422.     CrossRef
  • Emerging evidence of the relationship between fat-free mass and ghrelin, glucagon-like peptide-1, and peptide-YY
    Austin J. Graybeal, Jada L. Willis, Elisa Morales-Marroquin, Grant M. Tinsley, Sarah E. Messiah, Meena Shah
    Nutrition.2022; 103-104: 111815.     CrossRef
  • The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
    Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
    Medicines.2022; 9(9): 47.     CrossRef
  • Distribution of lean mass and mortality risk in patients with type 2 diabetes
    Li Ding, Yuxin Fan, Jingting Qiao, Jing He, Ruodan Wang, Qing He, Jingqiu Cui, Zhongshu Ma, Fangqiu Zheng, Hua Gao, Chenlin Dai, Hongyan Wei, Jun Li, Yuming Cao, Gang Hu, Ming Liu
    Primary Care Diabetes.2022; 16(6): 824.     CrossRef
  • Cardio-sarcopenia: A syndrome of concern in aging
    De Rong Loh, Ru-San Tan, Wee Shiong Lim, Angela S. Koh
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Type 2 diabetes
    Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R Webb, Melanie J Davies
    The Lancet.2022; 400(10365): 1803.     CrossRef
  • Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors
    Satoshi Katano, Toshiyuki Yano, Hidemichi Kouzu, Ryohei Nagaoka, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Katsuhiko Ohori, Nobutaka Nagano, Takefumi Fujito, Ryo Nishikawa, Wataru Ohwada, Masaki Katayose, Tatsuya Sato, Atsushi Kuno, Masato Furuhashi
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
    Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
    Expert Opinion on Pharmacotherapy.2021; 22(7): 889.     CrossRef
  • Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
    Andrew Grannell, William P. Martin, Babak Dehestani, Werd Al‐Najim, John C. Murphy, Carel W. le Roux
    Obesity.2021; 29(3): 529.     CrossRef
  • Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
    Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
    BMJ Open.2021; 11(4): e045844.     CrossRef
  • Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review
    Bethina Liu, Hugh E. Giffney, Rhonda S. Arthur, Thomas E. Rohan, Andrew J. Dannenberg
    Cancer Prevention Research.2021; 14(5): 509.     CrossRef
  • Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
    Khaoula Errafii, Neyla S. Al-Akl, Olfa Khalifa, Abdelilah Arredouani
    Journal of Translational Medicine.2021;[Epub]     CrossRef
  • Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
    Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
    Nutrition & Diabetes.2021;[Epub]     CrossRef
  • Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
    Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding, Stephen C. Bain
    Drugs.2021; 81(11): 1243.     CrossRef
  • Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years
    Riobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, Beatriz M Luchiari, Otavio R Coelho-Filho, Otavio R Coelho, Pedro Schwartzmann, Elza Muscellie, Wilson Nadruz, Luiz Sergio F Carvalho, Andrei C Sposito
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): 3060.     CrossRef
  • Physical activity and exercise in the management of type 2 diabetes: where to start?
    Deirdre Harrington, Joe Henson
    Practical Diabetes.2021; 38(5): 35.     CrossRef
  • Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes

    New England Journal of Medicine.2021; 385(22): 2105.     CrossRef
  • Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
    Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Kazuya Murata
    Current Diabetes Reviews.2021; 17(3): 293.     CrossRef
  • Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
    Hirotatsu Nakaguchi, Yoshinobu Kondo, Mayu Kyohara, Hiromi Konishi, Koji Oiwa, Yasuo Terauchi
    Journal of Diabetes Investigation.2020; 11(6): 1542.     CrossRef
  • Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
    Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell
    Nutrients.2020; 12(2): 510.     CrossRef
  • GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
    Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
    Cell Reports Medicine.2020; 1(1): 100006.     CrossRef
  • Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
    Haitham Abdulla, Bethan E. Phillips, Daniel J. Wilkinson, Marie Limb, Tereza Jandova, Joseph J. Bass, Debbie Rankin, Jessica Cegielski, Mariwan Sayda, Hannah Crossland, John P. Williams, Kenneth Smith, Iskandar Idris, Philip J. Atherton
    Aging Cell.2020;[Epub]     CrossRef
Close layer
Editorials
Miscellaneous
Being Indexed in SCIE: A Major Step Forward for Endocrinology and Metabolism
Won-Young Lee
Endocrinol Metab. 2019;34(3):263-264.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.263
  • 3,664 View
  • 39 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
    Jong Chul Won, Ki-Hyun Baek
    Endocrinology and Metabolism.2022; 37(6): 851.     CrossRef
Close layer
Diabetes
Comprehensive Efforts Are Needed to Improve the Quality of Primary Diabetes Care in Korea
Chan-Hee Jung
Endocrinol Metab. 2019;34(3):265-267.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.265
  • 3,624 View
  • 46 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
    Brian Godman, Mainul Haque, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Eleonora Allocati, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M Muksudul Alam, Iffat Jahan, Zubair Ma
    Current Medical Research and Opinion.2021; 37(9): 1529.     CrossRef
Close layer
Original Articles
Clinical Study
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
Endocrinol Metab. 2019;34(3):268-274.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.268
  • 7,413 View
  • 133 Download
  • 13 Web of Science
  • 13 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Graves' disease (GD) is an autoimmune thyroid disorder caused by antibodies stimulating the thyrotropin (TSH) receptor. TSH receptor antibody (TRAb) measurement is useful for predicting GD relapse after antithyroid drug (ATD) treatment. However, the association of other thyroid autoantibodies with GD relapse remains obscure.

Methods

This retrospective study enrolled patients with GD who were initially treated with ATD. TRAb, thyroid peroxidase antibody (TPOAb), and thyroglobulin antibody (TgAb) were measured at the initial diagnosis and at the time of ATD discontinuation.

Results

A total of 55 patients were enrolled. The mean age was 49.7 years, and 39 patients (70.9%) were female. Antibody positivity at diagnosis was 90.9%, 69.1%, and 61.9% for TRAb, TPOAb, TgAb, respectively. Median ATD treatment period was 15.1 months. At the time of ATD withdrawal, TRAb titers decreased uniformly overall. Conversely, TPOAb and TgAb showed various changes. After withdrawal of ATD, 19 patients (34.5%) experienced relapse. No clinical features or laboratory results were significantly related to relapse in the overall patient group. However, in the TPOAb positive group at diagnosis, increasing titer of TPOAb or TgAb after ATD treatment was significantly and independently related to relapse free survival (TPOAb: hazard ratio [HR], 17.99; 95% confidence interval [CI], 1.66 to 195.43; P=0.02) (TgAb: HR, 5.73; 95% CI, 1.21 to 27.26; P=0.03).

Conclusion

Changes in TPOAb or TgAb titers during treatment might be useful for predicting relapse after ATD treatment in patients with positive TPOAb at diagnosis.

Citations

Citations to this article as recorded by  
  • Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study
    Xinpan Wang, Tiantian Li, Yue Li, Qiuyi Wang, Yun Cai, Zhixiao Wang, Yun Shi, Tao Yang, Xuqin Zheng
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves’ disease: a cross-sectional study
    Masahito Katahira, Taku Tsunekawa, Akira Mizoguchi, Mariko Yamaguchi, Kahori Tsuru, Hiromi Takashima, Ryoma Terada
    Hormones.2023; 22(2): 253.     CrossRef
  • The Clinical Implications of Anti-thyroid Peroxidase Antibodies in Graves’ Disease in Basrah
    Emad S Alhubaish, Nassar T Alibrahim, Abbas A Mansour
    Cureus.2023;[Epub]     CrossRef
  • Influence of Thyroid Peroxidase Antibodies Serum Levels in Graves' Disease: A Retrospective Cohort Study
    Maria L Guia Lopes, Carlos Tavares Bello, José P Cidade, Clotilde Limbert, Joao Sequeira Duarte
    Cureus.2023;[Epub]     CrossRef
  • Interpretation of Thyroid Autoantibodies in Hyperthyroidism
    Han-Sang Baek, Dong-Jun Lim
    The Korean Journal of Medicine.2023; 98(3): 132.     CrossRef
  • Usefulness of Real-Time Quantitative Microvascular Ultrasonography for Differentiation of Graves’ Disease from Destructive Thyroiditis in Thyrotoxic Patients
    Han-Sang Baek, Ji-Yeon Park, Chai-Ho Jeong, Jeonghoon Ha, Moo Il Kang, Dong-Jun Lim
    Endocrinology and Metabolism.2022; 37(2): 323.     CrossRef
  • Differential Diagnosis of Thyrotoxicosis by Machine Learning Models with Laboratory Findings
    Jinyoung Kim, Han-Sang Baek, Jeonghoon Ha, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Dong-Jun Lim, Ki-Hyun Baek
    Diagnostics.2022; 12(6): 1468.     CrossRef
  • The relationship between atherosclerotic disease and relapse during ATD treatment
    Xinxin Zhu, Yaguang Zhang, Xiaoyu Zhao, Xiaona Zhang, Zixuan Ru, Yanmeizhi Wu, Xu Yang, Boyu Hou, Hong Qiao
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves’ Disease and Hashimoto’s Thyroiditis in Korean Patients
    Jee Hee Yoon, Min-ho Shin, Hee Nam Kim, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2021; 36(3): 599.     CrossRef
  • Low frequency of IL-10-producing B cells and high density of ILC2s contribute to the pathological process in Graves’ disease, which may be related to elevated-TRAb levels
    Xiaoyun Ji, Jie Wan, Rong Chen, Huixuan Wang, Lan Huang, Shwngjun Wang, Zhaoliang Su, Huaxi Xu
    Autoimmunity.2020; 53(2): 78.     CrossRef
  • Implication of VDR rs7975232 and FCGR2A rs1801274 gene polymorphisms in the risk and the prognosis of autoimmune thyroid diseases in the Tunisian population
    S Mestiri, I Zaaber, I Nasr, H Marmouch
    Balkan Journal of Medical Genetics.2020; 23(1): 69.     CrossRef
  • Thyroid Peroxidase Antibody Positivity is Associated With Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease
    Christopher A. Muir, Graham R.D. Jones, Jerry R. Greenfield, Andrew Weissberger, Katherine Samaras
    Endocrine Practice.2020; 26(9): 1026.     CrossRef
  • Predicting the Risk of Graves Disease Relapse: Commentary on “Thyroid Peroxidase Antibody Positivity is Associated with Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease”
    D. Gallo, M.L. Tanda, E. Piantanida
    Endocrine Practice.2020; 26(9): 1039.     CrossRef
Close layer
Clinical Study
Trends in Hyperglycemic Crisis Hospitalizations and in- and out-of-Hospital Mortality in the Last Decade Based on Korean National Health Insurance Claims Data
Ji Hong You, Sun Ok Song, Se Hee Park, Kyoung Hye Park, Joo Young Nam, Dong Wook Kim, Hyun Min Kim, Dong-Jun Kim, Yong-ho Lee, Byung-Wan Lee
Endocrinol Metab. 2019;34(3):275-281.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.275
  • 7,663 View
  • 100 Download
  • 9 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Hyperglycemic crisis is a metabolic emergency associated with diabetes mellitus. However, accurate epidemiologic information on cases of hyperglycemic crisis in Korea remains scarce. We evaluated trends in hyperglycemic crisis hospitalizations and in- and out-of-hospital mortality in Korea. We also predicted future trends.

Methods

We extracted claims data with hyperglycemic crisis as the principal diagnosis from the National Health Insurance Service database in Korea from January 2004 to December 2013. We investigated the numbers of claims with hyperglycemic crisis and identified trends in hyperglycemic crisis based on those claims data. We predicted future trends by statistical estimation.

Results

The total annual number of claims of hyperglycemic crisis increased from 2,674 in 2004 to 5,540 in 2013. Statistical analysis revealed an increasing trend in hyperglycemic crisis hospitalizations (P for trend <0.01). In contrast, the hospitalization rate per 1,000 diabetes cases showed a decreasing trend (P for trend <0.01) during this period. The mortality rate per 1,000 diabetes cases also showed a decreasing trend (P for trend <0.0001). However, no distinct linear trend in the case-related fatality rate at <60 days over the last decade was observed. The predicted number of annual claims of hyperglycemic crisis will increase by 2030.

Conclusion

The number of hyperglycemic crisis hospitalizations in Korea increased in the last decade, although the hospitalization rate per 1,000 diabetes cases and mortality rate decreased. Also, the predicted number of annual claims will increase in the future. Thus, it is necessary to establish long-term healthcare policies to prevent hyperglycemic crisis.

Citations

Citations to this article as recorded by  
  • Enhancing outcome prediction by applying the 2019 WHO DM classification to adults with hyperglycemic crises: A single-center cohort in Thailand
    Chatchon Kaewkrasaesin, Weerapat Kositanurit, Phawinpon Chotwanvirat, Nitchakarn Laichuthai
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(4): 103012.     CrossRef
  • Obesity and 30-day case fatality after hyperglycemic crisis hospitalizations in Korea: a national cohort study
    Hojun Yoon, Hyun Ho Choi, Giwoong Choi, Sun Ok Song, Kyoung Hwa Ha, Dae Jung Kim
    Cardiovascular Prevention and Pharmacotherapy.2023; 5(3): 74.     CrossRef
  • Interpreting global trends in type 2 diabetes complications and mortality
    Mohammed K. Ali, Jonathan Pearson-Stuttard, Elizabeth Selvin, Edward W. Gregg
    Diabetologia.2022; 65(1): 3.     CrossRef
  • Comparison of the clinical characteristics and outcomes of pediatric patients with and without diabetic ketoacidosis at the time of type 1 diabetes diagnosis
    Young-Jun Seo, Chang Dae Kum, Jung Gi Rho, Young Suk Shim, Hae Sang Lee, Jin Soon Hwang
    Annals of Pediatric Endocrinology & Metabolism.2022; 27(2): 126.     CrossRef
  • Clinical characteristics and outcomes of care in patients hospitalized with diabetic ketoacidosis
    Mohsen S. Eledrisi, Haifaa Alkabbani, Malk Aboawon, Aya Ali, Imad Alabdulrazzak, Maab Elhaj, Ashraf Ahmed, Hazim Alqahwachi, Joanne Daghfal, Salem A. Beshyah, Rayaz A. Malik
    Diabetes Research and Clinical Practice.2022; 192: 110041.     CrossRef
  • Hyperglycemic Crisis Characteristics and Outcome of Care in Adult Patients without and with a History of Diabetes in Tigrai, Ethiopia: Comparative Study
    Getachew Gebremedhin, Fikre Enqueselassie, Helen Yifter, Negussie Deyessa
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 547.     CrossRef
  • Increased Incidence of Pediatric Diabetic Ketoacidosis After COVID-19: A Two-Center Retrospective Study in Korea
    Min Jeong Han, Jun Ho Heo
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 783.     CrossRef
  • Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports
    Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi
    Diabetes & Metabolism Journal.2020; 44(2): 349.     CrossRef
  • Letter: Trends in Hyperglycemic Crisis Hospitalizations and in- and out-of-Hospital Mortality in the Last Decade Based on Korean National Health Insurance Claims Data (Endocrinol Metab 2019;34:275–81, Ji Hong You et al.)
    Jang Won Son
    Endocrinology and Metabolism.2019; 34(4): 422.     CrossRef
  • Response: Trends in Hyperglycemic Crisis Hospitalizations and in- and out-of-Hospital Mortality in the Last Decade Based on Korean National Health Insurance Claims Data (Endocrinol Metab 2019;34:275–81, Ji Hong You et al.)
    Ji Hong You, Sun Ok Song
    Endocrinology and Metabolism.2019; 34(4): 424.     CrossRef
Close layer
Clinical Study
Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea
Da Hea Seo, Shinae Kang, Yong-ho Lee, Jung Yoon Ha, Jong Suk Park, Byoung-Wan Lee, Eun Seok Kang, Chul Woo Ahn, Bong-Soo Cha
Endocrinol Metab. 2019;34(3):282-290.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.282
  • 6,224 View
  • 89 Download
  • 15 Web of Science
  • 15 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

This study investigated the overall status of diabetes control and screening for diabetic microvascular complications in patients with type 2 diabetes mellitus attending primary care clinics in Korea.

Methods

In this cross-sectional observational study, 191 primary care clinics were randomly selected across Korea from 2015 to 2016. In total, 3,227 subjects were enrolled in the study.

Results

The patients followed at the primary care clinics were relatively young, with a mean age of 61.4±11.7 years, and had a relatively short duration of diabetes (mean duration, 7.6±6.5 years). Approximately 14% of subjects had diabetic microvascular complications. However, the patients treated at the primary care clinics had suboptimal control of hemoglobin A1c levels, blood pressure, and serum lipid levels, along with a metabolic target achievement rate of 5.9% according to the Korean Diabetes Association guidelines. The screening rates for diabetic nephropathy, retinopathy, and neuropathy within the past 12 months were 28.4%, 23.3%, and 13.3%, respectively.

Conclusion

The overall status of diabetes management, including the frequency of screening for microvascular complications, was suboptimal in the primary care clinics. More efforts should be made and more resources need to be allocated for primary care physicians to promote adequate healthcare delivery, which would result in stricter diabetes control and improved management of diabetic complications.

Citations

Citations to this article as recorded by  
  • Risk of Cause-Specific Mortality across Glucose Spectrum in Elderly People: A Nationwide Population-Based Cohort Study
    Joonyub Lee, Hun-Sung Kim, Kee-Ho Song, Soon Jib Yoo, Kyungdo Han, Seung-Hwan Lee
    Endocrinology and Metabolism.2023; 38(5): 525.     CrossRef
  • Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus
    Ji Yoon Kim, Jimi Choi, Sin Gon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2023; 47(6): 837.     CrossRef
  • Effectiveness of quality of care for patients with type 2 diabetes in China: findings from the Shanghai Integration Model (SIM)
    Chun Cai, Yuexing Liu, Yanyun Li, Yan Shi, Haidong Zou, Yuqian Bao, Yun Shen, Xin Cui, Chen Fu, Weiping Jia
    Frontiers of Medicine.2022; 16(1): 126.     CrossRef
  • Comparison of Health Outcomes by Care Provider Type for Newly Diagnosed Mild Type 2 Diabetes Patients in South Korea: A Retrospective Cohort Study
    Hee-Chung Kang, Jae-Seok Hong
    Healthcare.2022; 10(2): 334.     CrossRef
  • Management Status of Patients with Type 2 Diabetes Mellitus at General Hospitals in Korea: A 5-Year Follow-Up Study
    Jin Hee Jung, Jung Hwa Lee, Hyang Mi Jang, Young Na, Hee Sun Choi, Yeon Hee Lee, Yang Gyo Kang, Na Rae Kim, Jeong Rim Lee, Bok Rye Song, Kang Hee Sim
    The Journal of Korean Diabetes.2022; 23(1): 64.     CrossRef
  • Type 2 Diabetes Mellitus with Early Dry Skin Disorder: A Comparison Study Between Primary and Tertiary Care in Indonesia
    Lili Legiawati, Kusmarinah Bramono, Wresti Indriatmi, Em Yunir, Aditya Indra Pratama
    Current Diabetes Reviews.2022;[Epub]     CrossRef
  • Long-Term Changes in HbA1c According to Blood Glucose Control Status During the First 3 Months After Visiting a Tertiary University Hospital
    Hyunah Kim, Da Young Jung, Seung-Hwan Lee, Jae-Hyoung Cho, Hyeon Woo Yim, Hun-Sung Kim
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Differences in health behavior and nutrient intake status between diabetes-aware and unaware Korean adults based on the Korea national health and nutrition examination survey 2016–18 data: A cross-sectional study
    Anshul Sharma, Chen Lulu, Kee-Ho Song, Hae-Jeung Lee
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Effects of Diabetes Quality Assessment on Diabetes Management Behaviors Based on a Nationwide Survey
    Chang Kyun Choi, Jungho Yang, Ji-An Jeong, Min-Ho Shin
    International Journal of Environmental Research and Public Health.2022; 19(23): 15781.     CrossRef
  • The Impact of the Indonesian Chronic Disease Management Program (PROLANIS) on Metabolic Control and Renal Function of Type 2 Diabetes Mellitus Patients in Primary Care Setting
    Firas Farisi Alkaff, Fauzan Illavi, Sovia Salamah, Wiwit Setiyawati, Ristra Ramadhani, Elly Purwantini, Dicky L. Tahapary
    Journal of Primary Care & Community Health.2021; 12: 215013272098440.     CrossRef
  • Questionnaire-based Survey of Demographic and Clinical Characteristics, Health Behaviors, and Mental Health of Young Korean Adults with Early-Onset Diabetes
    Ji In Park, Hyunjeong Baek, Sang-Wook Kim, Ji Yun Jeong, Kee-Ho Song, Ji Hee Yu, Il Sung Nam-Goong, Eun-Hee Cho
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study
    Min-Kyung Lee, Bongsung Kim, Kyungdo Han, Jae-Hyuk Lee, Minhee Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon, Young-Jung Roh
    Diabetes Care.2021; 44(10): 2419.     CrossRef
  • Challenges in the Management of Diabetes in Primary Care
    Yeon Kyung Lee
    The Journal of Korean Diabetes.2020; 21(3): 161.     CrossRef
  • Does Diabetes Increase the Risk of Contracting COVID-19? A Population-Based Study in Korea
    Sung-Youn Chun, Dong Wook Kim, Sang Ah Lee, Su Jung Lee, Jung Hyun Chang, Yoon Jung Choi, Seong Woo Kim, Sun Ok Song
    Diabetes & Metabolism Journal.2020; 44(6): 897.     CrossRef
  • Comprehensive Efforts Are Needed to Improve the Quality of Primary Diabetes Care in Korea
    Chan-Hee Jung
    Endocrinology and Metabolism.2019; 34(3): 265.     CrossRef
Close layer
Endocrine Research
Aldosterone Rapidly Enhances Levels of the Striatin and Caveolin-1 Proteins in Rat Kidney: The Role of the Mineralocorticoid Receptor
Kevalin Inthachart, Krissanapong Manotham, Somchai Eiam-Ong, Somchit Eiam-Ong
Endocrinol Metab. 2019;34(3):291-301.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.291
  • 4,481 View
  • 50 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Striatin and caveolin-1 (cav-1) are scaffolding/regulating proteins that are associated with salt-sensitive high blood pressure and promote renal sodium and water reabsorption, respectively. The mineralocorticoid receptor (MR) interacts with striatin and cav-1, while aldosterone increases striatin and cav-1 levels. However, no in vivo data have been reported for the levels of these proteins in the kidney.

Methods

Male Wistar rats were intraperitoneally injected with normal saline solution, aldosterone alone (Aldo: 150 µg/kg body weight), or aldosterone after pretreatment with eplerenone, an MR blocker, 30 minutes before the aldosterone injection (eplerenone [Ep.]+Aldo). Thirty minutes after the aldosterone injection, the amount and localization of striatin and cav-1 were determined by Western blot analysis and immunohistochemistry, respectively.

Results

Aldosterone increased striatin levels by 150% (P<0.05), and cav-1 levels by 200% (P<0.001). Eplerenone had no significant effect on striatin levels, but partially blocked the aldosterone-induced increase in cav-1 levels. Aldosterone stimulated striatin and cav-1 immunoreactivity in both the cortex and medulla. Eplerenone reduced cav-1 immunostaining in both areas; however, striatin intensity was reduced in the cortex, but increased in the medulla.

Conclusion

This is the first in vivo study demonstrating that aldosterone rapidly enhances renal levels of striatin and cav-1. Aldosterone increases striatin levels via an MR-independent pathway, whereas cav-1 is partially regulated through MR.

Citations

Citations to this article as recorded by  
  • Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
    Jin Young Lee, Da Ae Kim, Eunah Choi, Yun Sun Lee, So Jeong Park, Beom-Jun Kim
    Endocrinology and Metabolism.2021; 36(4): 865.     CrossRef
Close layer
Endocrine Research
Effects of Oxytocin on Cell Proliferation in a Corticotroph Adenoma Cell Line
Jung Soo Lim, Young Woo Eom, Eun Soo Lee, Hyeong Ju Kwon, Ja-Young Kwon, Junjeong Choi, Choon Hee Chung, Young Suk Jo, Eun Jig Lee
Endocrinol Metab. 2019;34(3):302-313.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.302
  • 5,623 View
  • 77 Download
  • 3 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Oxytocin (OXT) has been reported to act as a growth regulator in various tumor cells. However, there is a paucity of data on the influence of OXT on cell proliferation of corticotroph adenomas. This study aimed to examine whether OXT affects cell growth in pituitary tumor cell lines (AtT20 and GH3 cells) with a focus on corticotroph adenoma cells.

Methods

Reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay were conducted with AtT20 cells to confirm the effects of OXT on hormonal activity; flow cytometry was used to assess changes in the cell cycle after OXT treatment. Moreover, the impact of OXT on proliferating cell nuclear antigen (PCNA), nuclear factor κB, and mitogen-activated protein kinase signaling pathway was analyzed by Western blot.

Results

OXT treatment of 50 nM changed the gene expression of OXT receptor and pro-opiomelanocortin within a short time. In addition, OXT significantly reduced adrenocorticotropic hormone secretion within 1 hour. S and G2/M populations of AtT20 cells treated with OXT for 24 hours were significantly decreased compared to the control. Furthermore, OXT treatment decreased the protein levels of PCNA and phosphorylated extracellular-signal-regulated kinase (P-ERK) in AtT20 cells.

Conclusion

Although the cytotoxic effect of OXT in AtT20 cells was not definite, OXT may blunt cell proliferation of corticotroph adenomas by altering the cell cycle or reducing PCNA and P-ERK levels. Further research is required to investigate the role of OXT as a potential therapeutic target in corticotroph adenomas.

Citations

Citations to this article as recorded by  
  • Increased proliferation and neuronal fate in prairie vole brain progenitor cells cultured in vitro: effects by social exposure and sexual dimorphism
    Daniela Ávila-González, Italo Romero-Morales, Lizette Caro, Alejandro Martínez-Juárez, Larry J. Young, Francisco Camacho-Barrios, Omar Martínez-Alarcón, Analía E. Castro, Raúl G. Paredes, Néstor F. Díaz, Wendy Portillo
    Biology of Sex Differences.2023;[Epub]     CrossRef
  • Anterior pituitary gland synthesises dopamine from l‐3,4‐dihydroxyphenylalanine (l‐dopa)
    Santiago Jordi Orrillo, Nataly de Dios, Antonela Sofía Asad, Fernanda De Fino, Mercedes Imsen, Ana Clara Romero, Sandra Zárate, Jimena Ferraris, Daniel Pisera
    Journal of Neuroendocrinology.2020;[Epub]     CrossRef
Close layer
Endocrine Research
Transcriptome Analysis Identifies an Attenuated Local Immune Response in Invasive Nonfunctioning Pituitary Adenomas
Yong Hwy Kim, Jung Hee Kim
Endocrinol Metab. 2019;34(3):314-322.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.314
Correction in: Endocrinol Metab 2020;35(4):965
  • 5,566 View
  • 61 Download
  • 14 Web of Science
  • 12 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Invasive nonfunctioning pituitary adenomas (NFPAs) remain challenging due to their high complication rate and poor prognosis. We aimed to identify the distinctive molecular signatures of invasive NFPAs, compared with noninvasive NFPAs, using gene expression profiling by RNA sequencing.

Methods

We obtained frozen fresh tissue samples from 14 patients with NFPAs who underwent primary transsphenoidal surgery. Three non-invasive and 11 invasive NFPAs were used for RNA sequencing. The bioinformatics analysis included differential gene expression, gene ontology analysis, and pathway analysis.

Results

A total of 700 genes were differentially expressed (59 up-regulated and 641 down-regulated genes) between invasive and non-invasive NFPAs (false discovery rate <0.1, and |fold change| ≥2). Using the down-regulated genes in invasive NFPAs, gene ontology enrichment analyses and pathway analyses demonstrated that the local immune response was attenuated and that transforming growth factor-β (TGF-β) RII-initiated TGF-β signaling was down-regulated in invasive NFPAs. The overexpression of claudin-9 (CLDN9) and the down-regulation of insulin-like growth factor-binding protein 5 (IGFBP5), death-associated protein kinase 1 (DAPK1), and tissue inhibitor of metalloproteinase-3 (TIMP3) may be related with invasiveness in NFPAs.

Conclusion

Invasive NFPAs harbor different gene expression profiles relative to noninvasive NFPAs. In particular, local suppression of the immune response and TGF-β signaling can make PAs prone to invasiveness.

Citations

Citations to this article as recorded by  
  • Research status and prospects of pituitary adenomas in conjunction with neurological and psychiatric disorders and the tumor microenvironment
    Siyuan Cui, Sainan Chen, Xuechao Wu, Qing Wang
    Frontiers in Neuroscience.2024;[Epub]     CrossRef
  • Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors
    Xiaopeng Guo, Yiying Yang, Zhihong Qian, Mengqi Chang, Yuanli Zhao, Wenbin Ma, Yu Wang, Bing Xing
    Cancer Letters.2024; 592: 216908.     CrossRef
  • Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
    Rihards Saksis, Olesja Rogoza, Helvijs Niedra, Kaspars Megnis, Ilona Mandrika, Inga Balcere, Liva Steina, Janis Stukens, Austra Breiksa, Jurijs Nazarovs, Jelizaveta Sokolovska, Ilze Konrade, Raitis Peculis, Vita Rovite
    Cancer Cell International.2023;[Epub]     CrossRef
  • PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
    Giulia Cossu, Stefano La Rosa, Jean Philippe Brouland, Nelly Pitteloud, Ethan Harel, Federico Santoni, Maxime Brunner, Roy Thomas Daniel, Mahmoud Messerer
    Cancers.2023; 15(18): 4471.     CrossRef
  • Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways
    Simona Serioli, Ludovico Agostini, Alberto Pietrantoni, Federico Valeri, Flavia Costanza, Sabrina Chiloiro, Barbara Buffoli, Amedeo Piazza, Pietro Luigi Poliani, Maria Peris-Celda, Federica Iavarone, Simona Gaudino, Marco Gessi, Giovanni Schinzari, Pier P
    International Journal of Molecular Sciences.2023; 24(21): 15719.     CrossRef
  • Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine
    Siqi Wen, Chunling Li, Xianquan Zhan
    EPMA Journal.2022; 13(1): 9.     CrossRef
  • A systematic review of molecular alterations in invasive non-functioning pituitary adenoma
    Nazanin Hosseinkhan, Maryam Honardoost, Zahra Emami, Sara Cheraghi, Nahid Hashemi-Madani, Mohammad E. Khamseh
    Endocrine.2022; 77(3): 500.     CrossRef
  • Medication for Acromegaly Reduces Expression of MUC16, MACC1 and GRHL2 in Pituitary Neuroendocrine Tumour Tissue
    Rihards Saksis, Ivars Silamikelis, Pola Laksa, Kaspars Megnis, Raitis Peculis, Ilona Mandrika, Olesja Rogoza, Ramona Petrovska, Inga Balcere, Ilze Konrade, Liva Steina, Janis Stukens, Austra Breiksa, Jurijs Nazarovs, Jelizaveta Sokolovska, Valdis Pirags,
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Large Scale Molecular Studies of Pituitary Neuroendocrine Tumors: Novel Markers, Mechanisms and Translational Perspectives
    Raitis Peculis, Helvijs Niedra, Vita Rovite
    Cancers.2021; 13(6): 1395.     CrossRef
  • Nkx3-1 and Fech genes might be switch genes involved in pituitary non-functioning adenoma invasiveness
    Nasibeh Khayer, Maryam Jalessi, Amin Jahanbakhshi, Alireza Tabib khooei, Mehdi Mirzaie
    Scientific Reports.2021;[Epub]     CrossRef
  • The tumour microenvironment of pituitary neuroendocrine tumours
    Pedro Marques, Ashley B. Grossman, Márta Korbonits
    Frontiers in Neuroendocrinology.2020; 58: 100852.     CrossRef
  • The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas
    Congxin Dai, Siyu Liang, Bowen Sun, Jun Kang
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
Close layer
Letter
Close layer
Response
Thyroid
Response: Long-Term Outcomes Following Thermal Ablation of Benign Thyroid Nodules as an Alternative to Surgery: The Importance of Controlling Regrowth (Endocrinol Metab 2019;34:117–23, Jung Suk Sim et al.)
Jung Suk Sim, Jung Hwan Baek
Endocrinol Metab. 2019;34(3):325-326.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.325
[Original]
  • 3,713 View
  • 46 Download
  • 1 Web of Science
  • 2 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Five-year follow-up results of thermal ablation for benign thyroid nodules: Systematic review and meta-analysis
    Xidong Xu, Ying Peng, Guoxin Han
    American Journal of Otolaryngology.2024; 45(1): 104025.     CrossRef
  • How to Monitor and Manage Nodule Regrowth after Thermal Ablation of Benign Thyroid Nodules
    Sang Ik Park, Jung Hwan Baek
    Korean Journal of Radiology.2021; 22(2): 293.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism